var title_f27_59_28592="Surgical drainage of a breast abscess";
var content_f27_59_28592=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F63472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F63472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Surgical drainage of a breast abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 196px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin compromise necessitates incision and drainage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Dixon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_59_28592=[""].join("\n");
var outline_f27_59_28592=null;
var title_f27_59_28593="Calculator: Pulmonary Vascular Resistance";
var content_f27_59_28593=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"PulmVascResist_form\" name=\"PulmVascResist_form\" onkeydown=\"clrResults();\" onkeyup=\"PulmVascResist_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Pulmonary Vascular Resistance",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         PVR = 80 * ( MeanPulmonaryArteryPressure - LeftAtrialPressure) / PulmonaryFlow",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"      <tr>",
"       <td align=\"right\" width=\"50%\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Input:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Mean Pulmonary Artery Pressure",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Mean_Pulmonary_Artery_Pressure_param\" onblur=\"PulmVascResist_fx(); minMaxCheck();\" onchange=\"PulmVascResist_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Mean_Pulmonary_Artery_Pressure_unit\" onchange=\"PulmVascResist_fx();\" style=\"width:105px;\">",
"             <option value=\"0.00750063755419211|0|Pascal\">",
"              Pascal",
"             </option>",
"             <option value=\"760.002100178515|0|atm\">",
"              atm",
"             </option>",
"             <option value=\"750.063755419211|0|bar\">",
"              bar",
"             </option>",
"             <option value=\"0.735561538478802|0|cmH2O\">",
"              cmH2O",
"             </option>",
"             <option value=\"10|0|cmHg\">",
"              cmHg",
"             </option>",
"             <option value=\"22.4199156928339|0|ftH2O\">",
"              ftH2O",
"             </option>",
"             <option value=\"0.735561538478802|0|gm/sqcm\">",
"              gm/sqcm",
"             </option>",
"             <option value=\"1.86832630773616|0|inH2O\">",
"              inH2O",
"             </option>",
"             <option value=\"25.4000840071406|0|inHg\">",
"              inHg",
"             </option>",
"             <option value=\"7.50063755419211|0|kPa\">",
"              kPa",
"             </option>",
"             <option value=\"0.750063755419211|0|mbar\">",
"              mbar",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|mmHg\">",
"              mmHg",
"             </option>",
"             <option value=\"51.7150957831416|0|psi\">",
"              psi",
"             </option>",
"             <option value=\"1|0|torr\">",
"              torr",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Left Atrial Pressure",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Left_Atrial_Pressure_param\" onblur=\"PulmVascResist_fx(); minMaxCheck();\" onchange=\"PulmVascResist_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Left_Atrial_Pressure_unit\" onchange=\"PulmVascResist_fx();\" style=\"width:105px;\">",
"             <option value=\"0.00750063755419211|0|Pascal\">",
"              Pascal",
"             </option>",
"             <option value=\"760.002100178515|0|atm\">",
"              atm",
"             </option>",
"             <option value=\"750.063755419211|0|bar\">",
"              bar",
"             </option>",
"             <option value=\"0.735561538478802|0|cmH2O\">",
"              cmH2O",
"             </option>",
"             <option value=\"10|0|cmHg\">",
"              cmHg",
"             </option>",
"             <option value=\"22.4199156928339|0|ftH2O\">",
"              ftH2O",
"             </option>",
"             <option value=\"0.735561538478802|0|gm/sqcm\">",
"              gm/sqcm",
"             </option>",
"             <option value=\"1.86832630773616|0|inH2O\">",
"              inH2O",
"             </option>",
"             <option value=\"25.4000840071406|0|inHg\">",
"              inHg",
"             </option>",
"             <option value=\"7.50063755419211|0|kPa\">",
"              kPa",
"             </option>",
"             <option value=\"0.750063755419211|0|mbar\">",
"              mbar",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|mmHg\">",
"              mmHg",
"             </option>",
"             <option value=\"51.7150957831416|0|psi\">",
"              psi",
"             </option>",
"             <option value=\"1|0|torr\">",
"              torr",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Pulmonary Flow",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Pulmonary_Flow_param\" onblur=\"PulmVascResist_fx(); minMaxCheck();\" onchange=\"PulmVascResist_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Pulmonary_Flow_unit\" onchange=\"PulmVascResist_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|L/min\">",
"              L/min",
"             </option>",
"             <option value=\"60|0|L/sec\">",
"              L/sec",
"             </option>",
"             <option value=\"1.666666667e-05|0|mL/hr\">",
"              mL/hr",
"             </option>",
"             <option value=\"0.001|0|mL/min\">",
"              mL/min",
"             </option>",
"             <option value=\"0.06|0|mL/sec\">",
"              mL/sec",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Result:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             PVR",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"PVR_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <span style=\"white-space: nowrap;\">",
"              <span class=\"medCalcFontOneBold\">",
"               dynes-sec-cm",
"               <sup>",
"                -5",
"               </sup>",
"              </span>",
"             </span>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"3\">",
"            &nbsp;",
"            <br/>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"center\" colspan=\"3\">",
"            <span class=\"medCalcFontOneBold\">",
"             Decimal Precision:",
"            </span>",
"            <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"PulmVascResist_fx();\">",
"             <option>",
"              0",
"             </option>",
"             <option>",
"              1",
"             </option>",
"             <option selected=\"selected\">",
"              2",
"             </option>",
"             <option>",
"              3",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontOneBold\">",
"     Notes",
"    </span>",
"    <ul class=\"medCalcFontOne\">",
"     <li>",
"      In most cases",
"      <b>",
"       Pulmonary Flow",
"      </b>",
"      is equivalent to the cardiac output.",
"     </li>",
"     <li>",
"      Normal",
"      <b>",
"       PVR",
"      </b>",
"      is approximately 67 +- 30 dynes-sec-cm",
"      <sup>",
"       -5",
"      </sup>",
"      .",
"     </li>",
"    </ul>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontRef\">",
"     <b>",
"      References",
"     </b>",
"    </span>",
"    <ol>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       Baim D, ed.",
"       <i>",
"        Grossman's Cardiac Catheterization, Angiography, and Intervention",
"       </i>",
"       . Lipincott Williams &amp; Wilkins 7th Ed. 2006.",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       Barratt-Boyes BG, Wood EH. Cardiac output and related measurements and pressure values in the right heart and associated vessels,  together with an analysis of the hemo-dynamic response to the inhalation of high oxygen mixtures in healthy subjects.",
"       <i>",
"        J Lab Clin Med",
"       </i>",
"       . 1958 Jan;51(1):72-90.",
"      </span>",
"     </li>",
"    </ol>",
"   </form>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_59_28593=[" /* <![CDATA[ */",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function PulmVascResist_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.PulmVascResist_form){",
"",
"",
"doCalc = true;",
"if (Mean_Pulmonary_Artery_Pressure_param.value.indexOf(',') >= 0){ Mean_Pulmonary_Artery_Pressure_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Mean_Pulmonary_Artery_Pressure_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Mean_Pulmonary_Artery_Pressure_unit.options[Mean_Pulmonary_Artery_Pressure_unit.selectedIndex].value.split('|');",
"Mean_Pulmonary_Artery_Pressure = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Left_Atrial_Pressure_param.value.indexOf(',') >= 0){ Left_Atrial_Pressure_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Left_Atrial_Pressure_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Left_Atrial_Pressure_unit.options[Left_Atrial_Pressure_unit.selectedIndex].value.split('|');",
"Left_Atrial_Pressure = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Pulmonary_Flow_param.value.indexOf(',') >= 0){ Pulmonary_Flow_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Pulmonary_Flow_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Pulmonary_Flow_unit.options[Pulmonary_Flow_unit.selectedIndex].value.split('|');",
"Pulmonary_Flow = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"PVR =  80 * ( Mean_Pulmonary_Artery_Pressure - Left_Atrial_Pressure) / Pulmonary_Flow;",
"",
"if (doCalc) PVR_param.value = fixDP(PVR, dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.PulmVascResist_form){",
"",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.PulmVascResist_form){",
"",
"PVR_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"/* ]]> */"].join("\n");
var outline_f27_59_28593=null;
var title_f27_59_28594="Model of the HFE protein";
var content_f27_59_28594=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F57597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F57597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 512px\">",
"   <div class=\"ttl\">",
"    Model of the HFE protein",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 492px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hypothetical model of the HFE protein based upon its homology with MHC class I molecules. The HFE protein is a single polypeptide with three extracellular domains which would be analogous to the &alpha;1, &alpha;2, and &alpha;3 domains of other MHC class I proteins. In contrast to other members of the MHC class I family, the &alpha;1 and &alpha;2 domains in the HFE protein are nonpolymorphic. &beta;2-microglobulin is a separate protein and would interact with the HFE gene product in a noncovalent manner in the &alpha;3 homologous region. The HFE protein contains a membrane spanning region and a short cytoplasmic tail. The approximate locations of C282Y (the major mutation in hereditary hemochromatosis) and H63D are indicated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_59_28594=[""].join("\n");
var outline_f27_59_28594=null;
var title_f27_59_28595="Defibulation 2";
var content_f27_59_28595=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Defibulation (reversal of female genital infibulation)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Step 2: Make an anterior incision between the two Allis clamps with Mayo scissors, being certain not to cut into a buried clitoris.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_59_28595=[""].join("\n");
var outline_f27_59_28595=null;
var title_f27_59_28596="Phosphofructokinase deficiency (glycogen storage disease VII, Tarui disease)";
var content_f27_59_28596=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Phosphofructokinase deficiency (glycogen storage disease VII, Tarui disease)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/59/28596/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/59/28596/contributors\">",
"     William J Craigen, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/59/28596/contributors\">",
"     Basil T Darras, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/59/28596/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/59/28596/contributors\">",
"     Sihoun Hahn, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/59/28596/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/59/28596/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/59/28596/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glycogen is the stored form of glucose and serves as a buffer for glucose needs. It is composed of long polymers of a 1-4 linked glucose, interrupted by a 1-6 linked branch point every 4 to 10 residues. Glycogen is formed in periods of dietary carbohydrate loading and broken down when glucose demand is high or dietary availability is low (",
"    <a class=\"graphic graphic_figure graphicRef81164 \" href=\"UTD.htm?4/62/5089\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are a number of inborn errors of glycogen metabolism that result from mutations in genes for virtually all of the proteins involved in glycogen synthesis, degradation, or regulation. Those disorders that result in abnormal storage of glycogen are known as glycogen storage diseases (GSDs). They have largely been categorized by number according to the chronology of recognition of the responsible enzyme defect (",
"    <a class=\"graphic graphic_table graphicRef54417 \" href=\"UTD.htm?37/36/38477\">",
"     table 1",
"    </a>",
"    ). The age of onset varies from in utero to adulthood.",
"   </p>",
"   <p>",
"    Glycogen is most abundant in liver and muscle, which are most affected by these disorders. The physiologic importance of a given enzyme in liver and muscle determines the clinical manifestations of the disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The main role of glycogen in the liver is to store glucose for release to tissues that are unable to synthesize significant amounts during fasting. The major manifestations of disorders of glycogen metabolism affecting the liver are hypoglycemia and hepatomegaly. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=see_link\">",
"       \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glycogen is the primary source of energy for high-intensity muscle activity by providing substrates for the generation of ATP. The major manifestations of disorders of glycogen metabolism affecting muscle are muscle cramps, exercise intolerance and easy fatiguability, and progressive weakness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review muscle phosphofructokinase deficiency (GSD VII, MIM #232800), also known as Tarui disease. An overview of glycogen storage disease is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=see_link\">",
"     \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHOSPHOFRUCTOKINASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phosphofructokinase (PFK) is a glycolytic enzyme that catalyzes the conversion of fructose 6-phosphate to fructose 1,6-bisphosphate (",
"    <a class=\"graphic graphic_figure graphicRef81164 \" href=\"UTD.htm?4/62/5089\">",
"     figure 1",
"    </a>",
"    ). When PFK is deficient, the resulting block in glycolysis leads to a secondary glycogenosis.",
"   </p>",
"   <p>",
"    PFK is a tetrameric enzyme composed of three distinct subunits, L (liver), M (muscle), and P (platelet). Expression of the subunits is tissue specific. The enzyme in erythrocytes is a 50:50 hybrid of the M and L types [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28596/abstract/1\">",
"     1",
"    </a>",
"    ]. The vast majority of patients with GSD VII lack the muscle-specific isoform of PFK; normal isoforms are present in platelets and liver.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inheritance is autosomal recessive. The disorder is caused by mutations in the gene for the M isoform of PFK, located at 12q13 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28596/abstract/2\">",
"     2",
"    </a>",
"    ]. The genes for the L and P subunits have been mapped to chromosomes 21 and 10, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28596/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Partial deficiency of PFK activity is present in erythrocytes as a result of functional homotetramers of the liver subunit [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28596/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of mutations has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28596/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. A founder mutation is present in the majority of Ashkenazi Jewish patients that alters a splice site, leading to exon skipping [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28596/abstract/8\">",
"     8",
"    </a>",
"    ]. This splice site mutation and another single nucleotide deletion account for approximately 95 percent of the mutations responsible for muscle PFK deficiency in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28596/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disease typically presents in childhood with fatigue, muscle cramps, and exercise intolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28596/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. A high-carbohydrate meal or administration of glucose prior to exercise aggravates symptoms, due to decreased availability of free fatty acids and ketones [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28596/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients with PFK deficiency do not develop a spontaneous second wind under conditions that produce one in patients with McArdle disease (muscle phosphorylase deficiency) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28596/abstract/13\">",
"     13",
"    </a>",
"    ]; this seems to be related to the inability of PFK-deficient muscle to metabolize glucose.",
"   </p>",
"   <p>",
"    Patients often have exertional rhabdomyolysis with myoglobinuria. Some have erythrocyte hemolysis, a feature of several disorders of glycolysis. This usually is compensated by increased red blood cell production. Hyperuricemia and gout may be seen and can occur in the absence of clinically apparent skeletal muscle involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28596/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Presentation sometimes occurs in middle age to late adulthood with fixed muscle weakness and progressive atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28596/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. There are case reports of infants with apparent deficiency of all three isoforms of phosphofructokinase, associated with central nervous system disease, skeletal myopathy, and cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28596/abstract/18\">",
"     18",
"    </a>",
"    ]. A case presenting with neonatal epilepsy has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28596/abstract/19\">",
"     19",
"    </a>",
"    ]. The mechanism that accounts for multisystem disease is unknown, but may be due to absence of an activator that is common to all the isoforms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum creatine kinase concentration is usually elevated. Red blood cell PFK activity is typically reduced to approximately one-half of normal. A mild hemolytic anemia may be present, sometimes with mild hyperbilirubinemia. Patients often have hyperuricemia, due to increased degradation of purine nucleotides in muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28596/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The ischemic forearm exercise test shows no rise in lactate levels.",
"   </p>",
"   <p>",
"    Muscle biopsy reveals a modest increase in subsarcolemmal glycogen that has a normal appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28596/abstract/20\">",
"     20",
"    </a>",
"    ]. In older patients, an abnormal polysaccharide with a filamentous fine-structure resembling that of glycogen brancher enzyme deficiency may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28596/abstract/21\">",
"     21",
"    </a>",
"    ]. Phosphofructokinase activity is deficient in muscle and is reduced in erythrocytes.",
"   </p>",
"   <p>",
"    Among patients of Ashkenazi Jewish ancestry, diagnosis through genetic testing for the two most common mutations in this population has been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28596/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific treatment for this disorder. Patients should avoid strenuous exercise. In one patient with infantile onset, cardiomyopathy improved with a ketogenic diet that was used to bypass the glycolytic block, although he subsequently died [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28596/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phosphofructokinase (PFK) is a glycolytic enzyme that catalyzes the conversion of fructose 6-phosphate to fructose 1,6-bisphosphate (",
"      <a class=\"graphic graphic_figure graphicRef81164 \" href=\"UTD.htm?4/62/5089\">",
"       figure 1",
"      </a>",
"      ). Deficiency of PFK results in secondary glycogenosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Phosphofructokinase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PFK deficiency (also known ad glycogen storage disease VII and Tarui disease) has an autosomal recessive inheritance pattern. It is caused by a variety of mutations in the gene for the M isoform of PFK. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PFK deficiency typically presents in childhood with fatigue, muscle cramps, and exercise intolerance. These symptoms may be exacerbated when exercise is preceded by a high-carbohydrate meal or administration of glucose. Additional findings may include exertional rhabdomyolysis with myoglobinuria, erythrocyte hemolysis, hyperuricemia and gout. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory features suggestive of the diagnosis may include elevated serum creatine kinase, decreased red blood cell PFK activity (to approximately one-half of normal), mild hemolytic anemia, and hyperuricemia. The ischemic forearm exercise test shows no rise in lactate levels. The diagnosis is confirmed with muscle biopsy demonstrating deficient PFK activity, or alternatively by detecting DNA mutations of known pathogenicity. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no specific treatment for the more common form of the disease. Patients should avoid strenuous exercise. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28596/abstract/1\">",
"      Ronquist G, Rudolphi O, Engstr&ouml;m I, Waldenstr&ouml;m A. Familial phosphofructokinase deficiency is associated with a disturbed calcium homeostasis in erythrocytes. J Intern Med 2001; 249:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28596/abstract/2\">",
"      Howard TD, Akots G, Bowden DW. Physical and genetic mapping of the muscle phosphofructokinase gene (PFKM): reassignment to human chromosome 12q. Genomics 1996; 34:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28596/abstract/3\">",
"      Van Keuren M, Drabkin H, Hart I, et al. Regional assignment of human liver-type 6-phosphofructokinase to chromosome 21q22.3 by using somatic cell hybrids and a monoclonal anti-L antibody. Hum Genet 1986; 74:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28596/abstract/4\">",
"      Vora S, Miranda AF, Hernandez E, Francke U. Regional assignment of the human gene for platelet-type phosphofructokinase (PFKP) to chromosome 10p: novel use of polyspecific rodent antisera to localize human enzyme genes. Hum Genet 1983; 63:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28596/abstract/5\">",
"      DiMauro S, Miranda AF, Sakoda S, et al. Metabolic myopathies. Am J Med Genet 1986; 25:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28596/abstract/6\">",
"      Raben N, Sherman JB. Mutations in muscle phosphofructokinase gene. Hum Mutat 1995; 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28596/abstract/7\">",
"      Nichols RC, Rudolphi O, Ek B, et al. Glycogenosis type VII (Tarui disease) in a Swedish family: two novel mutations in muscle phosphofructokinase gene (PFK-M) resulting in intron retentions. Am J Hum Genet 1996; 59:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28596/abstract/8\">",
"      Raben N, Sherman J, Miller F, et al. A 5' splice junction mutation leading to exon deletion in an Ashkenazic Jewish family with phosphofructokinase deficiency (Tarui disease). J Biol Chem 1993; 268:4963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28596/abstract/9\">",
"      Raben N, Sherman JB, Adams E, et al. Various classes of mutations in patients with phosphofructokinase deficiency (Tarui's disease). Muscle Nerve 1995; 3:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28596/abstract/10\">",
"      TARUI S, OKUNO G, IKURA Y, et al. PHOSPHOFRUCTOKINASE DEFICIENCY IN SKELETAL MUSCLE. A NEW TYPE OF GLYCOGENOSIS. Biochem Biophys Res Commun 1965; 19:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28596/abstract/11\">",
"      Layzer RB, Rowland LP, Ranney HM. Muscle phosphofructokinase deficiency. Arch Neurol 1967; 17:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28596/abstract/12\">",
"      Haller RG, Lewis SF. Glucose-induced exertional fatigue in muscle phosphofructokinase deficiency. N Engl J Med 1991; 324:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28596/abstract/13\">",
"      Haller RG, Vissing J. No spontaneous second wind in muscle phosphofructokinase deficiency. Neurology 2004; 62:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28596/abstract/14\">",
"      Mineo I, Kono N, Hara N, et al. Myogenic hyperuricemia. A common pathophysiologic feature of glycogenosis types III, V, and VII. N Engl J Med 1987; 317:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28596/abstract/15\">",
"      Mineo I, Tarui S. Myogenic hyperuricemia: what can we learn from metabolic myopathies? Muscle Nerve 1995; 3:S75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28596/abstract/16\">",
"      Danon MJ, Servidei S, DiMauro S, Vora S. Late-onset muscle phosphofructokinase deficiency. Neurology 1988; 38:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28596/abstract/17\">",
"      Sivakumar K, Vasconcelos O, Goldfarb L, Dalakas MC. Late-onset muscle weakness in partial phosphofructokinase deficiency: a unique myopathy with vacuoles, abnormal mitochondria, and absence of the common exon 5/intron 5 junction point mutation. Neurology 1996; 46:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28596/abstract/18\">",
"      Amit R, Bashan N, Abarbanel JM, et al. Fatal familial infantile glycogen storage disease: multisystem phosphofructokinase deficiency. Muscle Nerve 1992; 15:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28596/abstract/19\">",
"      Al-Hassnan ZN, Al Budhaim M, Al-Owain M, et al. Muscle phosphofructokinase deficiency with neonatal seizures and nonprogressive course. J Child Neurol 2007; 22:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28596/abstract/20\">",
"      Bonilla E, Schotland DL. Histochemical diagnosis of muscle phosphofructokinase deficiency. Arch Neurol 1970; 22:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28596/abstract/21\">",
"      Hays AP, Hallett M, Delfs J, et al. Muscle phosphofructokinase deficiency: abnormal polysaccharide in a case of late-onset myopathy. Neurology 1981; 31:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28596/abstract/22\">",
"      Swoboda KJ, Specht L, Jones HR, et al. Infantile phosphofructokinase deficiency with arthrogryposis: clinical benefit of a ketogenic diet. J Pediatr 1997; 131:932.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2907 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-199.231.185.123-2733C36ADC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_59_28596=[""].join("\n");
var outline_f27_59_28596=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHOSPHOFRUCTOKINASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2907\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2907|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/62/5089\" title=\"figure 1\">",
"      Pathways of glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2907|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/36/38477\" title=\"table 1\">",
"      Disorders of glycogen - glucose metabolism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=related_link\">",
"      Overview of inherited disorders of glucose and glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=related_link\">",
"      Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_59_28597="Buruli ulcer lower leg";
var content_f27_59_28597=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Buruli ulcer located on the lower leg",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large, undermined lesion at the left lower leg in a 30-year-old female farmer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tjip S van der Werf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_59_28597=[""].join("\n");
var outline_f27_59_28597=null;
var title_f27_59_28598="Calcium carbonate and magnesium hydroxide: Drug information";
var content_f27_59_28598=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Calcium carbonate and magnesium hydroxide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/50/11044?source=see_link\">",
"    see \"Calcium carbonate and magnesium hydroxide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mi-Acid&trade; Double Strength [OTC];",
"     </li>",
"     <li>",
"      Mylanta&reg; Gelcaps&reg; [OTC];",
"     </li>",
"     <li>",
"      Mylanta&reg; Supreme [OTC];",
"     </li>",
"     <li>",
"      Mylanta&reg; Ultra [OTC];",
"     </li>",
"     <li>",
"      Rolaids&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Rolaids&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F144355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antacid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F144351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hyperacidity: Oral: 2-4 tablets between meals, at bedtime, or as directed by healthcare provider",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F144352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F144342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gelcap (Mylanta&reg; Gelcaps&reg;): Calcium carbonate 550 mg and magnesium hydroxide 125 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid (Mylanta&reg; Supreme): Calcium carbonate 400 mg and magnesium hydroxide 135 mg per 5 mL (360 mL, 720 mL) [cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mi-Acid&trade; Double Strength: Calcium carbonate 700 mg and magnesium hydroxide 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mylanta&reg; Ultra: Calcium carbonate 700 mg and magnesium hydroxide 300 mg [cherry cr&eacute;me and cool mint flavors]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rolaids&reg;: Calcium carbonate 550 mg and magnesium hydroxide 110 mg [sodium free; contains elemental calcium 220 mg and elemental magnesium 45 mg; original (peppermint), cherry, and spearmint flavors]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rolaids&reg; Extra Strength: Calcium carbonate 675 mg and magnesium hydroxide 135 mg [sodium free; contains elemental calcium 271 mg and elemental magnesium 56 mg, fruit flavor contains tartrazine; cool strawberry, fresh mint, fruit, and tropical fruit punch flavors]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F144335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Chewable tablet",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F144343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hyperacidity",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F144359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Mylanta&reg; may be confused with Mynatal&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F144340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Antacids may decrease the serum concentration of ACE Inhibitors.  Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Enalaprilat; Ramipril.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfacalcidol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Antacids may decrease the absorption of Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Antacids may decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antacids may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Antacids may decrease the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antacids may decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Antacids may decrease the absorption of Atazanavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisacodyl: Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Antacids may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Magnesium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Antacids may decrease the serum concentration of Bosutinib.  Management: Administer antacids more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Acetate: Calcium Salts may enhance the adverse/toxic effect of Calcium Acetate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Laxatives may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of calcium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of calcium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives or sorbitol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the cation exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of CPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Antacids may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy. If antacid therapy can not be avoided, separate dosing by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefpodoxime: Antacids may decrease the serum concentration of Cefpodoxime.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefuroxime: Antacids may decrease the serum concentration of Cefuroxime.  Management:  Consider administering antacids and cefuroxime at least 2 hours apart.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloroquine: Antacids may decrease the serum concentration of Chloroquine.  Management: Separate administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chloroquine bioavailability.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Oral): Antacids may decrease the bioavailability of Corticosteroids (Oral).  Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Antacids may decrease the serum concentration of Dabigatran Etexilate.  Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other situations, administer dabigatran etexilate 2 hours prior to antacids. Monitor clinical response to dabigatran therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Antacids may decrease the absorption of Dasatinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Antacids may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Calcium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Magnesium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Antacids may decrease the serum concentration of Delavirdine.  Management: Separate doses of delavirdine and antacids by at least 1 hour. Monitor for decreased delavirdine therapeutic effects with this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Antacids may increase the absorption of Dexmethylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Calcium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Magnesium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., magnesium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Antacids may decrease the serum concentration of Elvitegravir.  Management: Separate administration of antacids and the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product by at least 2 hours in order to minimize the risk for an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Antacids may decrease the serum concentration of Erlotinib.  Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estramustine: Calcium Salts may decrease the absorption of Estramustine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fexofenadine: Antacids may decrease the serum concentration of Fexofenadine.  Management: No specific recommendations concerning the time required between their administration are provided. Separate administration of each agent by as much time as possible to decrease the risk of an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gabapentin: Antacids may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after antacid administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Antacids may decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Antacids may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Antacids may decrease the absorption of Isoniazid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Antacids may decrease the serum concentration of Itraconazole.  Management: Administer itraconazole at least 1 hour after and 2 hours before administration of any antacids.  Itraconazole oral suspension may be less sensitive to the effects of decreased gastric acidity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Antacids may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any antacid product.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Antacids may diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Avoid concurrent administration of antacids with sustained-release mesalamine products.  Separating antacid and mesalamine administration, and/or using lower antacid doses may be adequate means of avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: Antacids may diminish the therapeutic effect of Methenamine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antacids may increase the absorption of Methylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Misoprostol: Antacids may enhance the adverse/toxic effect of Misoprostol. More specifically, concomitant use with magnesium-containing antacids may increase the risk of diarrhea.  Management: Avoid concomitant use of misoprostol and magnesium-containing antacids. In patients requiring antacid therapy, employ magnesium-free preparations. Monitor for increased adverse effects (e.g., diarrhea, dehydration).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Antacids may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, antacids may decrease the absorption of orally administered iron.  Management: Separate dosing of oral iron-containing multivitamin preparations and antacids by as much time as possible in order to minimize impact on therapeutic efficacy of the iron preparation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Calcium Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Antacids may decrease the absorption of Mycophenolate.  Management: Separate doses of mycophenolate and antacids by at least 2 hours. Monitor for reduced effects of mycophenolate if taken concomitant with antacids.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Magnesium Salts may decrease the serum concentration of Mycophenolate.  Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Antacids may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and any antacid by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: Antacids may decrease the serum concentration of PenicillAMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Antacids may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral magnesium salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Antacids may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Antacids may decrease the absorption of Protease Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Darunavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Antacids may decrease the excretion of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Antacids may decrease the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Antacids may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of quinolones.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Calcium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Moxifloxacin (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Magnesium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Antacids may decrease the serum concentration of Rilpivirine.  Management: Administer antacids at least 2 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Laxatives may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of sodium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of sodium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives or sorbitol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of SPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Calcium Salts may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and oral calcium salts by at least 2 hours in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Magnesium Hydroxide may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and magnesium hydroxide by at least 2 hours whenever possible in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Antacids may decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Magnesium Salts may decrease the absorption of Tetracycline Derivatives. Only applicable to oral preparations of each agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Calcium Salts may decrease the serum concentration of Tetracycline Derivatives.  Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Calcium Salts may diminish the therapeutic effect of Thyroid Products.  Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Antacids may decrease the absorption of Trientine.  Management: Separate trientine dosing from other oral drugs (eg, antacids) by at least 1 hour. Monitor for decreased therapeutic effects of trientine if an antacid is initiated/dose increased, or increased effects if an antacid is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Calcium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Calcium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Magnesium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Antacids may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14287005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F144346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Mi-Acid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     700-300 mg (70): $4.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Mylanta Ultra Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     700-300 mg (70): $4.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Rolaids Extra Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     675-135 mg (10): $0.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Rolaids Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     550-110 mg (12): $0.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Mylanta Supreme Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400-135 mg/5 mL (355 mL): $5.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Mylanta Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     311-232 mg (24): $2.77",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Mylanta 2go Rolltabs (NZ);",
"     </li>",
"     <li>",
"      Mylanta Rolltab (CO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F144345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8986 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-203.80.222.8-5CA963D2D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_59_28598=[""].join("\n");
var outline_f27_59_28598=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144348\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144355\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144351\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144352\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144342\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144335\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144343\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144359\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298935\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144340\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287004\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287005\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144346\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390209\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144345\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8986\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8986|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/50/11044?source=related_link\">",
"      Calcium carbonate and magnesium hydroxide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_59_28599="Echo AV valve regurgitation postsurgery of AV canal defect";
var content_f27_59_28599=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1263px;\">",
"  <div class=\"videoplayer\" h264=\"./images/PEDS/86877/Echo_AV_valve_regurg_video.mp4?title=Echo+AV+valve+regurgitation+postsurgery+of+AV+canal+defect\" style=\"width:496px;height:384px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 647px\">",
"   <div class=\"ttl\">",
"    Echocardiogram of atrioventricular (AV) valve regurgitation after surgical repair of AV canal defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 627px; height: 510px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Echocardiogram in a patient following surgical repair atrioventricular (AV) canal demonstrates left AV valve regurgitation (mitral valve regurgitation) (arrow) viewed from the apical 4 chamber view.",
"    <div class=\"footnotes\">",
"     LA: left atrium; LV: left ventricle; LAVV: left atrioventricular valve; LAVVR: left atrioventricular valve regurgitation; bpm: beats per minute.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_59_28599=[""].join("\n");
var outline_f27_59_28599=null;
var title_f27_59_28600="Types and pathophysiology of obstructive hypertrophic cardiomyopathy";
var content_f27_59_28600=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Types and pathophysiology of obstructive hypertrophic cardiomyopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/59/28600/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/59/28600/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/59/28600/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/59/28600/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/59/28600/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/59/28600/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/59/28600/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertrophic cardiomyopathy (HCM) is a genetically determined heart muscle disease most often (60 to 70 percent) caused by mutations in one of several sarcomere genes which encode components of the contractile apparatus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=see_link\">",
"     \"Genetics of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HCM is characterized by left ventricular hypertrophy of various morphologies, with a wide array of clinical manifestations and hemodynamic abnormalities (",
"    <a class=\"graphic graphic_figure graphicRef58156 \" href=\"UTD.htm?11/9/11411\">",
"     figure 1",
"    </a>",
"    ). Depending in part upon the site and extent of cardiac hypertrophy, HCM patients can develop one or more of the following abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      LV outflow obstruction",
"     </li>",
"     <li>",
"      Diastolic dysfunction",
"     </li>",
"     <li>",
"      Myocardial ischemia",
"     </li>",
"     <li>",
"      Mitral regurgitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These structural and functional abnormalities can produce a variety of symptoms, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fatigue",
"     </li>",
"     <li>",
"      Dyspnea",
"     </li>",
"     <li>",
"      Chest pain",
"     </li>",
"     <li>",
"      Palpitations",
"     </li>",
"     <li>",
"      Presyncope or syncope",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In broad terms, the symptoms related to HCM can be categorized as those related to heart failure (HF), chest pain, or arrhythmias. Patients with HCM have an increased incidence of both supraventricular and ventricular arrhythmias and are at an increased risk for sudden cardiac death (SCD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=see_link\">",
"     \"Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A resting or exercise provoked left ventricular outflow tract (LVOT) gradient is present in most patients with HCM (70 percent). Significant LVOT obstruction at rest, present in 20 to 30 percent, is an independent predictor of poor prognosis in patients with HCM. Four major approaches are available for treatment of LVOT obstruction in patients with HCM:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pharmacologic therapy",
"     </li>",
"     <li>",
"      Septal myectomy",
"     </li>",
"     <li>",
"      Nonsurgical septal reduction with alcohol (ethanol) ablation",
"     </li>",
"     <li>",
"      Dual chamber pacing (which has only a limited role)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review the types and pathophysiology of the LVOT obstruction and its clinical consequences. Other issues such as the clinical manifestations, natural history, diagnosis and evaluation, and treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link\">",
"     \"Natural history of hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=see_link\">",
"     \"Medical therapy in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=see_link\">",
"     \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF OBSTRUCTION IN HCM",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is significant interpatient variability in the degree of left ventricular outflow tract (LVOT) obstruction in HCM. Significant LVOT obstruction at rest is a constant finding in some patients with HCM (",
"    <a class=\"graphic graphic_waveform graphicRef65202 \" href=\"UTD.htm?29/22/30054\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef66652 \" href=\"UTD.htm?36/21/37207\">",
"     waveform 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/1-9\">",
"     1-9",
"    </a>",
"    ]. In others, there is no evidence of LV outflow obstruction at rest, but significant obstruction occurs under certain conditions (",
"    <a class=\"graphic graphic_waveform graphicRef65235 \" href=\"UTD.htm?11/28/11717\">",
"     waveform 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LVOT obstruction can be induced or increased by maneuvers that reduce preload (chamber size), decrease afterload, or increase left ventricular inotropy. Preload is reduced by dehydration, sudden adoption of the upright posture, the Valsalva maneuver, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/1/33813?source=see_link\">",
"       amyl nitrite",
"      </a>",
"      inhalation. Conditions associated with increased inotropy include fever, exercise,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"       isoproterenol",
"      </a>",
"      infusion, or postextrasystolic potentiation (ie, increased inotropy after an extrasystolic beat). The increased LVOT gradient and reduced aortic pulse pressure caused by postextrasystolic potentiation is known as the Brockenbrough sign. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3737?source=see_link&amp;anchor=H10#H10\">",
"       \"Hemodynamics of valvular disorders as measured by cardiac catheterization\", section on 'Augmentation of the gradient'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      LVOT obstruction can be reduced or eliminated by maneuvers that increase chamber size. This can be achieved by enhancing venous return and preload (eg, by squatting or leg elevation) or by raising afterload (eg, by handgrip).",
"     </li>",
"     <li>",
"      Drugs that reduce inotropy (eg, beta blockers, some calcium channel blockers, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"       disopyramide",
"      </a>",
"      ) also diminish obstruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some cases, HCM is complicated by marked spontaneous changes in LVOT obstruction under basal conditions. The LVOT pressure gradient can vary between zero and very high values within a few heart beats (",
"    <a class=\"graphic graphic_waveform graphicRef65749 \" href=\"UTD.htm?36/41/37527\">",
"     waveform 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Septal hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with the classic form of obstructive HCM, the LVOT is narrowed by a combination of septal hypertrophy and systolic anterior motion of the mitral valve (SAM). (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Mechanism of obstruction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are, in addition, several variants of obstructive HCM (",
"    <a class=\"graphic graphic_figure graphicRef58156 \" href=\"UTD.htm?11/9/11411\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Midcavity obstructive HCM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated midventricular obstruction is an uncommon morphologic variant of HCM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The midcavity obstruction is due to the systolic apposition of hypertrophied papillary muscle and LV wall at the level of the mid-LV, producing two distinct LV chambers. This disorder has been described in families with mutations of the essential or regulatory light chains of myosin heavy chain [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/12\">",
"     12",
"    </a>",
"    ]. The mutations may disrupt the stretch activation response of the papillary muscles, which could explain the prominent papillary muscle hypertrophy in this disorder.",
"   </p>",
"   <p>",
"    Patients with midcavity obstructive HCM are often symptomatic. Clinical examination reveals the typical signs of dynamic obstructive HCM, eg, a systolic murmur that accentuates with exercise or a change to an upright posture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41876?source=see_link\">",
"     \"Physiologic and pharmacologic maneuvers in the differential diagnosis of heart murmurs and sounds\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Echocardiography in the pure form of midcavity HCM shows absence of systolic anterior motion of the mitral valve and a narrowed mid-LV cavity with an apical LV pouch. High Doppler velocities, indicating a midcavity gradient, are recorded at the level of the papillary muscle. Color Doppler demonstrates a mosaic pattern at this level, confirming that the level of obstruction is below the mitral valve leaflets. In some patients, the midcavity obstruction is associated with a large apical left ventricular aneurysm which may be the site of origin of a rapid monomorphic ventricular tachycardia (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59767 \" href=\"UTD.htm?14/19/14640\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Apical HCM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apical HCM is another uncommon morphologic variant of HCM in which the hypertrophy of the myocardium predominantly involves the apex of the left ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. These patients do not have LVOT obstruction but may have midventricular obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Apical HCM appears to be particularly common in Asia. It has been reported in up to 41 percent of HCM patients in China [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/16\">",
"     16",
"    </a>",
"    ] and in 15 percent of HCM patients in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/17\">",
"     17",
"    </a>",
"    ]. In non-Asian populations, most reports suggest a prevalence of 1 to 3 percent of HCM patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/15,17,18\">",
"     15,17,18",
"    </a>",
"    ]. A study which directly compared findings in Japanese and European centers utilizing the same definitions and methodology, however, found a predominantly distal pattern of hypertrophy in 13 percent of Japanese and 11 percent of Europeans [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/19\">",
"     19",
"    </a>",
"    ], suggesting that there may not be significant differences in prevalence of apical HCM between Asians and other racial groups.",
"   </p>",
"   <p>",
"    Sarcomere gene mutations, similar to those seen in the usual types of HCM, were identified in 7 of 15 probands with apical HCM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/20\">",
"     20",
"    </a>",
"    ]. The cause in the remaining eight patients, seven of whom had a negative family history, and the additional factors that lead to isolated apical involvement are not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=see_link\">",
"     \"Genetics of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Typical features of apical HCM include an audible and palpable fourth heart sound, reflecting impaired left ventricular relaxation; \"giant\" T wave negativity on the ECG, particularly in the left precordial leads; and a \"spade-like configuration of the left ventricular cavity at end-diastole on left ventriculography. Associated apical wall motion abnormalities include hypokinesis and aneurysm formation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/14\">",
"     14",
"    </a>",
"    ]. The diagnosis can be made with echocardiography, left ventriculography, computed tomography, or most accurately with cardiovascular magnetic resonance (CMR) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/15,21,22\">",
"     15,21,22",
"    </a>",
"    ]. In one series, echocardiography detected an apical aneurysm in only 16 of 28 (57 percent) patients with apical aneurysm but CMR detected the 12 missed aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with apical HCM present with no or mild symptoms although presentation with heart failure, myocardial infarction, atrial fibrillation or ventricular fibrillation has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Those with symptoms may have angina, atypical chest pain, palpitations, presyncope or syncope. Fatigue and dyspnea may be caused by diastolic heart failure. Symptoms are often mild but a minority of patients have refractory symptoms of dyspnea, angina and presyncope or syncope due to diastolic dysfunction and low cardiac output. Apical myectomy has been reported as a potential option in such cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22696?source=see_link\">",
"     \"Overview of hypertrophic cardiomyopathy management including treatment of special problems\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The apical variant has a better mortality prognosis than other forms of HCM but is still associated with a relatively high rate of important cardiac events.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 105 patients with apical HCM (mean age 41) followed for a mean of 13.6 years, the total cardiovascular mortality rate was 1.9 and overall estimated survival was 95 percent at 15 years [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/14\">",
"       14",
"      </a>",
"      ]. However, 30 percent of patients experienced a serious cardiac complication, most commonly atrial fibrillation (12 percent) or a myocardial infarction (10 percent) that was mostly apical and mostly associated with normal coronary arteries. The probability of survival free of a cardiac event was 74 percent at 15 years.",
"     </li>",
"     <li>",
"      In a series of 28 HCM patients with apical aneurysms with a mean of 4 years follow-up, 12 (43 percent) experienced adverse complications including sudden cardiac death (n = 2, including one with prior nonfatal thromboembolic stroke), aborted cardiac arrest (n = 2), appropriate implantable cardioverter-defibrillator intervention (n = 3, including one with embolic stroke), and progressive heart failure with worsening functional status",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      death (n = 5) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Complex obstructive HCM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another subgroup, complex obstructive HCM, consists of obstruction at the level of both the papillary muscle (mid-LV cavity) and the mitral valve leaflets (LVOT) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Some patients have coexistent mid-right ventricular obstruction (",
"    <a class=\"graphic graphic_figure graphicRef58156 \" href=\"UTD.htm?11/9/11411\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Obstructive HCM in elderly adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive HCM may have its onset in elderly adults. The following clinical features have been noted [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In comparison to younger patients, individuals with late onset disease tend to have milder hypertrophy that is localized to the anterior interventricular septum, and an ovoid or ellipsoid (rather than crescentic) left ventricular cavity. Hypertension is more frequent than in younger subjects, but its role in triggering the development of hypertrophy is unclear.",
"     </li>",
"     <li>",
"      Systolic anterior motion of the mitral valve and LVOT gradients in older patients tend to be associated with very narrow left ventricular outflow tracts, anterior displacement of the entire mitral valve apparatus, and a larger area of contact between the mitral valve leaflet and the septum than in younger subjects with HCM.",
"     </li>",
"     <li>",
"      Obstructive HCM in elderly adults is not infrequently complicated by aortic sclerosis or stenosis. Severe aortic stenosis may mask underlying LV obstruction. As a result, echocardiography may show calcific aortic stenosis in association with a markedly hypertrophied and asymmetric LV. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38279?source=see_link\">",
"       \"Aortic valve sclerosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A characteristic feature of some cases of late onset disease is increased angulation of the aorta with respect to the long axis of the left ventricle. This may reflect age-related \"shrinkage\" of the heart resulting in an upper septal bulge (sigmoid septum) and narrowing of the LVOT. These changes occur in older adults with and without HCM. This sigmoid septal morphology is less commonly associated with a mutation than other HCM morphologic variants.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Issues related to the genetics and natural history of HCM in older patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=see_link&amp;anchor=H21#H21\">",
"     \"Genetics of hypertrophic cardiomyopathy\", section on 'HCM in the elderly'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link&amp;anchor=H3#H3\">",
"     \"Natural history of hypertrophic cardiomyopathy\", section on 'Late onset disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY AND EVOLUTION OF LV OUTFLOW OBSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification of factors that contribute to the development of LVOT obstruction was facilitated by the advent of 2-D echocardiography, with subsequent correlation of the echocardiographic with hemodynamic and cineangiographic findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3737?source=see_link\">",
"     \"Hemodynamics of valvular disorders as measured by cardiac catheterization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Mechanism of obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the LVOT is narrowed in classic obstructive HCM by a combination of septal hypertrophy and by anterior displacement of the mitral valve [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/4-9,29\">",
"     4-9,29",
"    </a>",
"    ]. The inward movement of the interventricular septum during systole further narrows the LVOT; this results in high LVOT blood velocities which pull the mitral valve leaflet toward the interventricular septum (Venturi effect).",
"   </p>",
"   <p>",
"    The systolic anterior motion (SAM) of the mitral valve is, in many patients, the most important determinant of the severity of LVOT obstruction. SAM usually involves only the anterior mitral valve leaflet but the posterior leaflet and chordal structures may also be involved. High LV systolic pressures are recorded just below the level of the mitral valve leaflet-septal coaptation, while the systolic pressures above this point are similar to those in the aorta. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\", section on 'LVOT obstruction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some patients with SAM and a posteriorly directed jet of mitral regurgitation, the LVOT obstruction occurs in association with LV cavity elimination and near complete systolic emptying [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. A substantial body of echocardiographic, hemodynamic, and cineangiographic evidence, however, indicates that in the majority of patients with a resting LVOT gradient &gt;50 mmHg associated with SAM and mitral regurgitation there is true obstruction to LV outflow, and that mitral valve-septal contact is responsible for the subaortic pressure gradient and the mitral regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/4-8,29,34\">",
"     4-8,29,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The magnitude of pressure gradients measured at cardiac catheterization correlate well with Doppler velocities and with the duration of SAM. Prolonged mitral valve-septal coaptation (&gt;30 percent of systole) is invariably associated with high pressure gradients and mild to severe mitral regurgitation. On the other hand, brief septal contact and less severe SAM is not associated with significant subvalvular aortic LV pressure gradients or mitral regurgitation.",
"     </li>",
"     <li>",
"      In obstructive HCM, there is often an area of scarring at the site of forceful repetitive contact of the mitral leaflet with the septum (contact lesion).",
"     </li>",
"     <li>",
"      Color Doppler studies localize the origins of the high outflow tract velocities to the site of mitral valve leaflet septal contact. There is acceleration of the jet proximal to the contact point and narrowing of the jet at the level of the mitral septal contact.",
"     </li>",
"     <li>",
"      The onset of mid-systolic partial closure of the aortic valve and abrupt LV systolic deceleration (recorded just below the aortic valve) occur at the same time as the onset of the mitral-septal contact.",
"     </li>",
"     <li>",
"      At cardiac catheterization, a systolic pressure gradient is recorded between the aorta and a freely moving catheter in the LV. Blood can be aspirated through this catheter during the entire cardiac cycle, indicating the absence of catheter entrapment within the hyperdynamic LV. These findings show that the high pressure readings within the ventricle during systole are not an artifact of catheter entrapment.",
"     </li>",
"     <li>",
"      Although some patients with LVOT gradients of &gt;50 mmHg have mild or no symptoms, in most patients, the magnitude of the gradient relates to symptoms and exercise limitation which provides the rationale for treatments aimed at gradient reduction. Factors that aggravate LVOT obstruction increase or induce symptoms such as syncope and ischemic chest pain [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/35\">",
"       35",
"      </a>",
"      ]. Conversely, therapies that reduce LVOT obstruction alleviate symptoms.",
"     </li>",
"     <li>",
"      LVOT obstruction is associated with increased myocardial lactate production, while relief of LVOT obstruction (eg, after cardiac surgery) is associated with less angina, less dyspnea, and improved myocardial perfusion. The reductions in LV systolic pressures and LVOT gradients in the latter setting are accompanied by a significant elevation in systemic arterial pressure and a fall in LV end-diastolic, left atrial, and pulmonary arterial pressures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Development of mitral regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to producing subaortic obstruction, SAM of the mitral valve also results in varying degrees of mitral regurgitation due to a gap between the mitral leaflets. There are, however, great interindividual differences in mitral regurgitation at comparable degrees of SAM of the mitral valve. One study analyzed mitral geometry with transesophageal echocardiography in 23 patients with obstructive HCM undergoing surgery; differences in leaflet length and mobility appeared to influence the extent of mitral regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/36\">",
"     36",
"    </a>",
"    ]. SAM produced greater mitral regurgitation if the posterior leaflet was limited in its ability to move anteriorly and participate in SAM and to coapt effectively. This was determined both by the length of the posterior leaflet and by the range of motion permitted by its chordal and papillary muscle connections (",
"    <a class=\"graphic graphic_figure graphicRef54090 \" href=\"UTD.htm?17/16/17665\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Despite the presence of several variables which influence mitral regurgitation, there is, nonetheless a correlation between the severity of mitral regurgitation and the LVOT gradient. In one study of 93 patients without independent mitral valve disease, the mean LVOT gradient in those with trivial, mild, moderate, and severe mitral regurgitation was 23, 44, 70, and 104 mmHg, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Evolution of LV outflow tract obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of LVOT obstruction usually coincides with the period of most rapid growth in childhood (",
"    <a class=\"graphic graphic_algorithm graphicRef62353 \" href=\"UTD.htm?17/8/17550\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/34,38\">",
"     34,38",
"    </a>",
"    ]. If present earlier, the degree of obstruction usually increases during this period. In addition, some children who initially present with nonobstructive HCM develop echocardiographic signs of significant resting obstruction. The development and progression of LVOT obstruction is due to increases in both proximal septal hypertrophy and anterior migration of the mitral valve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Late wall thinning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive LV wall thinning occurs in approximately 10 to 15 percent of HCM patients, and may be marked and more common in those with severe (&gt;3 cm) LVH at initial evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/39\">",
"     39",
"    </a>",
"    ]. This is associated with deterioration in LV systolic and diastolic function, and may be accompanied by loss of signs of LV outflow obstruction. When wall thinning is marked it is usually associated with a significant decrease in systolic function. This stage has been termed \"end-stage\" or \"burned out\" HCM and is seen in up to 5 percent of patients from large cohorts (",
"    <a class=\"graphic graphic_figure graphicRef81390 \" href=\"UTD.htm?7/27/7614\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link&amp;anchor=H5#H5\">",
"     \"Natural history of hypertrophic cardiomyopathy\", section on 'End-stage HCM'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Arguments against true obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the reasons just described, the prevalent view is that obstructive HCM is characterized in the majority by true obstruction to LV outflow which is an important determinant of clinical outcome. However, some investigators have argued against the existence of true obstruction and have proposed alternative explanations for the LV pressure gradients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/30-32,40\">",
"     30-32,40",
"    </a>",
"    ]. The following observations have been put forward as arguments against the presence of true obstruction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In contrast to aortic valvular stenosis, LV emptying is rapid and more complete in obstructive HCM.",
"     </li>",
"     <li>",
"      Most of the LV stroke volume is ejected prior to development of the pressure gradient. Indeed, the more severe pressure gradients are found in patients with the highest LV ejection fractions. The pressure gradients are attributed to the rapidly emptying and obliterating LV cavity below the mitral valve (Gauer-Henry phenomenon).",
"     </li>",
"     <li>",
"      Other investigators have contended that true obstruction to outflow is confined to only a few patients who have very small LV cavities and very large papillary muscles [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28600/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon such observations, it has been argued that nonpharmacologic therapy for obstruction such as surgical myectomy or nonsurgical septal ablation is indicated in only a minority of patients. The experience of most centers, however, is that the majority of patients with a resting LVOT gradient &gt;50 mmHg have true obstruction and benefit from treatments targeted at gradient reduction. Indeed, nonpharmacologic therapy is recommended in patients with obstruction who experience persistent moderate to severe symptoms or exercise limitation despite maximal tolerated drug therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=see_link\">",
"     \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/28/35266?source=see_link\">",
"       \"Patient information: Hypertrophic cardiomyopathy in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=see_link\">",
"       \"Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14370275\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant LVOT obstruction at rest is a constant finding in 20 to 30 percent of patients with HCM, while an additional 20 to 30 percent have no evidence of LVOT obstruction at rest but develop significant obstruction under certain conditions (reduced preload, reduced afterload, increased ventricular inotropy). The prognostic and therapeutic implications of provocable obstruction remain to be determined, but treatment of the symptomatic patient should focus on gradient reduction. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Types of obstruction in HCM'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with the classic form of obstructive HCM have the LVOT narrowed by a combination of septal hypertrophy and systolic anterior motion of the mitral valve (SAM). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Septal hypertrophy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Isolated midventricular obstruction is an uncommon morphologic variant of HCM which is due to the systolic apposition of hypertrophied papillary muscle and LV wall at the level of the mid-LV, producing two distinct LV chambers. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Midcavity obstructive HCM'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Apical HCM is another uncommon morphologic variant of HCM in which the hypertrophy of the myocardium predominantly involves the apex of the left ventricle. These patients do not have LVOT obstruction but may have midventricular obstruction. Apical HCM appears to be particularly common in Asia. In contrast to many patients with LVOT obstruction and most patients with midcavity obstruction, most patients with apical HCM present with no or mild symptoms. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Apical HCM'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obstructive HCM may have its onset in elderly adults. In comparison with younger patients, individuals with late onset disease tend to have milder hypertrophy that is localized to the anterior interventricular septum, and an ovoid or ellipsoid (rather than crescentic) left ventricular cavity. Systolic anterior motion of the mitral valve and LVOT gradients in older patients tend to be associated with very narrow left ventricular outflow tracts, anterior displacement of the entire mitral valve apparatus, and a larger area of contact between the mitral valve leaflet and the septum than in younger subjects with HCM. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Obstructive HCM in elderly adults'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=see_link&amp;anchor=H21#H21\">",
"       \"Genetics of hypertrophic cardiomyopathy\", section on 'HCM in the elderly'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link&amp;anchor=H3#H3\">",
"       \"Natural history of hypertrophic cardiomyopathy\", section on 'Late onset disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The LVOT is narrowed in classic obstructive HCM by a combination of septal hypertrophy and by anterior displacement of the mitral valve. The inward movement of the interventricular septum during systole further narrows the LVOT; this results in high LVOT blood velocities which pull the mitral valve leaflet toward the interventricular septum (Venturi effect). SAM of the mitral valve is, in many patients, the most important determinant of the severity of LVOT obstruction. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Mechanism of obstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although some patients with LVOT gradients of &gt;50 mmHg have mild or no symptoms, in most patients the magnitude of the gradient relates to symptoms and exercise limitation, which provides the rationale for treatments aimed at gradient reduction. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Mechanism of obstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to producing subaortic obstruction, SAM of the mitral valve also results in varying degrees of mitral regurgitation due to a gap between the mitral leaflets. There are, however, interindividual differences in mitral regurgitation at comparable degrees of SAM of the mitral valve. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Development of mitral regurgitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The development of LVOT obstruction usually coincides with the period of most rapid growth in childhood, with the development and progression of LVOT obstruction being relative to increases in both proximal septal hypertrophy and anterior migration of the mitral valve. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Evolution of LV outflow tract obstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy for patients with HCM and symptomatic LVOT obstruction is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22696?source=see_link\">",
"       \"Overview of hypertrophic cardiomyopathy management including treatment of special problems\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=see_link\">",
"       \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=see_link\">",
"       \"Medical therapy in hypertrophic cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/1\">",
"      WIGLE ED, HEIMBECKER RO, GUNTON RW. Idiopathic ventricular septal hypertrophy causing muscular subaortic stenosis. Circulation 1962; 26:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/2\">",
"      Pierce GE, Morrow AG, Braunwald E. Idiopathic hypertrophic subaortic stenosis. 3. Intraoperative studies of the mechanism of obstruction and its hemodynamic consequences. Circulation 1964; 30:Suppl.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/3\">",
"      Braunwald E, Lambrew CT, Rockoff SD, et al. Idiopathic hypertrophic subaortic stenosis. I. A description of the disease based upon an analysis of 64 patients. Circulation 1964; 30:Suppl.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/4\">",
"      Pollick C, Morgan CD, Gilbert BW, et al. Muscular subaortic stenosis: the temporal relationship between systolic anterior motion of the anterior mitral leaflet and the pressure gradient. Circulation 1982; 66:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/5\">",
"      Maron BJ, Gottdiener JS, Arce J, et al. Dynamic subaortic obstruction in hypertrophic cardiomyopathy: analysis by pulsed Doppler echocardiography. J Am Coll Cardiol 1985; 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/6\">",
"      Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis 1985; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/7\">",
"      Maron BJ, Epstein SE. Clinical significance and therapeutic implications of the left ventricular outflow tract pressure gradient in hypertrophic cardiomyopathy. Am J Cardiol 1986; 58:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/8\">",
"      Maron BJ, Bonow RO, Cannon RO 3rd, et al. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med 1987; 316:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/9\">",
"      Wigle ED. Hypertrophic cardiomyopathy: a 1987 viewpoint. Circulation 1987; 75:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/10\">",
"      Falicov RE, Resnekov L. Mid ventricular obstruction in hypertrophic obstructive cardiomyopathy. New diagnostic and therapeutic challenge. Br Heart J 1977; 39:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/11\">",
"      Fighali S, Krajcer Z, Edelman S, Leachman RD. Progression of hypertrophic cardiomyopathy into a hypokinetic left ventricle: higher incidence in patients with midventricular obstruction. J Am Coll Cardiol 1987; 9:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/12\">",
"      Poetter K, Jiang H, Hassanzadeh S, et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet 1996; 13:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/13\">",
"      Sakamoto T. Apical hypertrophic cardiomyopathy (apical hypertrophy): an overview. J Cardiol 2001; 37 Suppl 1:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/14\">",
"      Eriksson MJ, Sonnenberg B, Woo A, et al. Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 39:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/15\">",
"      Maron MS, Finley JJ, Bos JM, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation 2008; 118:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/16\">",
"      Ho HH, Lee KL, Lau CP, Tse HF. Clinical characteristics of and long-term outcome in Chinese patients with hypertrophic cardiomyopathy. Am J Med 2004; 116:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/17\">",
"      Kitaoka H, Doi Y, Casey SA, et al. Comparison of prevalence of apical hypertrophic cardiomyopathy in Japan and the United States. Am J Cardiol 2003; 92:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/18\">",
"      Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995; 26:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/19\">",
"      Chikamori T, Doi YL, Akizawa M, et al. Comparison of clinical, morphological, and prognostic features in hypertrophic cardiomyopathy between Japanese and western patients. Clin Cardiol 1992; 15:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/20\">",
"      Arad M, Penas-Lado M, Monserrat L, et al. Gene mutations in apical hypertrophic cardiomyopathy. Circulation 2005; 112:2805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/21\">",
"      Pons-Llad&oacute; G, Carreras F, Borr&aacute;s X, et al. Comparison of morphologic assessment of hypertrophic cardiomyopathy by magnetic resonance versus echocardiographic imaging. Am J Cardiol 1997; 79:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/22\">",
"      Moon JC, Fisher NG, McKenna WJ, Pennell DJ. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart 2004; 90:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/23\">",
"      Parker DP, Kaplan MA, Connolly JE. Coexistent aortic valvular and functional hypertrophic subaortic stenosis. Clinical , physiologic and angiographic aspects. Am J Cardiol 1969; 24:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/24\">",
"      Block PC, Powell WJ Jr, Dinsmore RE, Goldblatt A. Coexistent fixed congenital and idiopathic hypertrophic subaortic stenosis. Am J Cardiol 1973; 31:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/25\">",
"      Lewis JF, Maron BJ. Elderly patients with hypertrophic cardiomyopathy: a subset with distinctive left ventricular morphology and progressive clinical course late in life. J Am Coll Cardiol 1989; 13:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/26\">",
"      Fay WP, Taliercio CP, Ilstrup DM, et al. Natural history of hypertrophic cardiomyopathy in the elderly. J Am Coll Cardiol 1990; 16:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/27\">",
"      Chikamori T, Doi YL, Yonezawa Y, et al. Comparison of clinical features in patients greater than or equal to 60 years of age to those less than or equal to 40 years of age with hypertrophic cardiomyopathy. Am J Cardiol 1990; 66:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/28\">",
"      Lever HM, Karam RF, Currie PJ, Healy BP. Hypertrophic cardiomyopathy in the elderly. Distinctions from the young based on cardiac shape. Circulation 1989; 79:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/29\">",
"      Panza JA, Petrone RK, Fananapazir L, Maron BJ. Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1992; 19:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/30\">",
"      Criley JM, Lewis KB, White RI Jr, Ross RS. Pressure gradients without obstruction. A new concept of \"hypertrophic subaortic stenosis\". Circulation 1965; 32:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/31\">",
"      Murgo JP, Alter BR, Dorethy JF, et al. Dynamics of left ventricular ejection in obstructive and nonobstructive hypertrophic cardiomyopathy. J Clin Invest 1980; 66:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/32\">",
"      Criley JM. Unobstructed thinking (and terminology) is called for in the understanding and management of hypertrophic cardiomyopathy. J Am Coll Cardiol 1997; 29:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/33\">",
"      Sugrue DD, McKenna WJ, Dickie S, et al. Relation between left ventricular gradient and relative stroke volume ejected in early and late systole in hypertrophic cardiomyopathy. Assessment with radionuclide cineangiography. Br Heart J 1984; 52:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/34\">",
"      Panza JA, Maris TJ, Maron BJ. Development and determinants of dynamic obstruction to left ventricular outflow in young patients with hypertrophic cardiomyopathy. Circulation 1992; 85:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/35\">",
"      Maron BJ, Epstein SE, Roberts WC. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. Am J Cardiol 1979; 43:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/36\">",
"      Schwammenthal E, Nakatani S, He S, et al. Mechanism of mitral regurgitation in hypertrophic cardiomyopathy: mismatch of posterior to anterior leaflet length and mobility. Circulation 1998; 98:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/37\">",
"      Yu EH, Omran AS, Wigle ED, et al. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy. J Am Coll Cardiol 2000; 36:2219.",
"     </a>",
"    </li>",
"    <li>",
"     Maron BJ. Evolution of left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. In: Advances in Cardiomyopathies, Baroldi G, Camerini F, Goodwin JF (Eds), Springer-Verlag, Berlin, Heidelberg 1990. p.7.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28600/abstract/39\">",
"      Thaman R, Gimeno JR, Reith S, et al. Progressive left ventricular remodeling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy. J Am Coll Cardiol 2004; 44:398.",
"     </a>",
"    </li>",
"    <li>",
"     Goodwin JF. The management of hypertrophic cardiomyopathy based on symptoms, natural history, and prognosis. In: Cardiomyopathy Update 2. Hypertrophic Cardiomyopathy, Toshima H, Maron BJ (Eds), University Of Tokyo Press, Tokyo 1988. p.335.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4947 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-7727F3B860-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_59_28600=[""].join("\n");
var outline_f27_59_28600=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14370275\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF OBSTRUCTION IN HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Septal hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Midcavity obstructive HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Apical HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Complex obstructive HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Obstructive HCM in elderly adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOPHYSIOLOGY AND EVOLUTION OF LV OUTFLOW OBSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Mechanism of obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Development of mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Evolution of LV outflow tract obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Late wall thinning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Arguments against true obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14370275\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4947\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4947|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?17/8/17550\" title=\"algorithm 1\">",
"      LV remodeling HCM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4947|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/19/14640\" title=\"diagnostic image 1\">",
"      LV aneurysm in midcavity HCM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4947|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/9/11411\" title=\"figure 1\">",
"      Morphologic variants HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/16/17665\" title=\"figure 2\">",
"      Pathophysiology MR in HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/27/7614\" title=\"figure 3\">",
"      Pathogenesis end stage HCM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4947|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?29/22/30054\" title=\"waveform 1\">",
"      Invasive hemodynamic tracing HCM with LVOT obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?36/21/37207\" title=\"waveform 2\">",
"      Invasive hemodynamic tracing HCM with LVOT obstruction 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?11/28/11717\" title=\"waveform 3\">",
"      Invasive hemodynamic tracing provoked LVOT gradient in HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?36/41/37527\" title=\"waveform 4\">",
"      Invasive hemodynamic tracing HCM with variable LVOT obstruction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38279?source=related_link\">",
"      Aortic valve sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=related_link\">",
"      Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=related_link\">",
"      Genetics of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3737?source=related_link\">",
"      Hemodynamics of valvular disorders as measured by cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=related_link\">",
"      Medical therapy in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=related_link\">",
"      Natural history of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=related_link\">",
"      Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22696?source=related_link\">",
"      Overview of hypertrophic cardiomyopathy management including treatment of special problems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/28/35266?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41876?source=related_link\">",
"      Physiologic and pharmacologic maneuvers in the differential diagnosis of heart murmurs and sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=related_link\">",
"      Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_59_28601="Evaluation and management of asymptomatic left ventricular systolic dysfunction";
var content_f27_59_28601=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and management of asymptomatic left ventricular systolic dysfunction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/59/28601/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/59/28601/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/59/28601/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/59/28601/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/59/28601/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/59/28601/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/59/28601/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular (LV) systolic dysfunction with symptoms of heart failure (HF) is a common clinical problem. Population-based studies suggest that asymptomatic LV dysfunction is at least as prevalent as symptomatic HF in the general population.",
"   </p>",
"   <p>",
"    Patients with asymptomatic LV systolic dysfunction progress to overt HF over time. In the placebo arm of the SOLVD trial, patients with asymptomatic LV dysfunction not treated with an angiotensin converting enzyme (ACE) inhibitor progressed to symptomatic HF at a rate of 9.7 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, the mortality rate in patients with asymptomatic LV dysfunction is increased, although to a lesser degree than in symptomatic HF (",
"    <a class=\"graphic graphic_figure graphicRef60648 \" href=\"UTD.htm?28/60/29645\">",
"     figure 1",
"    </a>",
"    ). In the placebo arm of the SOLVD trial, the three-year mortality rate was 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Chronic LV systolic dysfunction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The management of patients with asymptomatic LV systolic dysfunction will be reviewed here. Issues related to the prevalence of and possible screening for asymptomatic LV systolic dysfunction and the management of symptomatic systolic HF are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20679?source=see_link\">",
"     \"Screening for asymptomatic left ventricular dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Asymptomatic LV diastolic dysfunction is also common and associated with an adverse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/2\">",
"     2",
"    </a>",
"    ]. However, there are no data on the efficacy of treating diastolic dysfunction before the onset of symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link&amp;anchor=H13537491#H13537491\">",
"     \"Treatment and prognosis of diastolic heart failure\", section on 'Asymptomatic diastolic dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;By definition, patients with asymptomatic LV dysfunction have no symptoms. The diagnosis is usually made by echocardiography performed because the patient might have underlying heart disease or cardiomegaly is detected on chest x-ray.",
"   </p>",
"   <p>",
"    These patients also should have no clear physical findings of HF (pulmonary rales, mild lower extremity edema). However, more subtle abnormalities may be present. In a review of 4100 patients from the SOLVD prevention trial, 5.1 percent had an S3 gallop and 1.7 percent had an elevated jugular venous pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/3\">",
"     3",
"    </a>",
"    ]. After adjusting for other markers of disease severity, these two findings were each associated with an increased risk of progression to overt HF (relative risk 1.38 and 1.51 compared to those without an S3 gallop). One limitation to these observations is the operator-dependence for the detection of these physical findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Neurohumoral activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to a low LVEF, patients with asymptomatic left ventricular systolic dysfunction show signs of secondary neurohumoral activation. The serum concentrations of norepinephrine, renin, antidiuretic hormone, and atrial and brain natriuretic peptides are elevated (",
"    <a class=\"graphic graphic_figure graphicRef55557 \" href=\"UTD.htm?20/13/20701\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/4-9\">",
"     4-9",
"    </a>",
"    ], reaching levels intermediate between age-matched controls and patients with symptomatic heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32455?source=see_link\">",
"     \"Pathophysiology of heart failure: Neurohumoral adaptations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The degree of neurohumoral activation is predictive of outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In the SOLVD trial, for example, elevated serum norepinephrine concentrations predicted mortality (all-cause and cardiovascular) and clinical events related to the subsequent onset of heart failure or acute ischemic syndromes (",
"    <a class=\"graphic graphic_figure graphicRef66349 \" href=\"UTD.htm?14/33/14878\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=see_link&amp;anchor=H15#H15\">",
"     \"Predictors of survival in heart failure due to systolic dysfunction\", section on 'Neurohumoral activation and heart rate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of asymptomatic LV systolic dysfunction is made from the history and from the demonstration of a reduced LVEF, most often by echocardiography. In some patients, echocardiography is performed to assess LV function because of known heart disease (eg, prior myocardial infarction). In other cases, echocardiography is performed for some other reason and a low LVEF is noted. In this setting, further evaluation is required to establish the cause of the LV dysfunction.",
"   </p>",
"   <p>",
"    The evaluation is similar to that in patients with symptomatic heart failure, including the need to identify causes such as underlying coronary artery disease and various etiologies of cardiomyopathy as discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=see_link\">",
"     \"Evaluation of the patient with heart failure or cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Familial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been estimated that as many as 20 to more than 50 percent of cases of idiopathic dilated cardiomyopathy are familial. It is therefore possible to detect evidence of early disease by screening asymptomatic family members, an approach that is recommended by the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines and others [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/59/5047?source=see_link&amp;anchor=H1365129#H1365129\">",
"     \"Familial dilated cardiomyopathy: Prevalence, diagnosis and treatment\", section on 'Diagnosis of familial disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This was illustrated in a prospective cohort study that evaluated (by echocardiography) 767 asymptomatic first- and second-degree relatives of 189 consecutive patients with idiopathic dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/11\">",
"     11",
"    </a>",
"    ]. There were two major findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dilated cardiomyopathy, left ventricular enlargement without systolic dysfunction, or systolic dysfunction without left ventricular enlargement was present in 23 percent of relatives.",
"     </li>",
"     <li>",
"      At a median follow-up of 53 months, 13 of the 124 relatives (10.4 percent) with left ventricular enlargement without systolic dysfunction or systolic dysfunction without left ventricular enlargement progressed to dilated cardiomyopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon observations such as these, some have suggested initiating therapy with an ACE inhibitor to slow progression in patients with left ventricular enlargement, even in the absence of a reduced LVEF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/12\">",
"     12",
"    </a>",
"    ]. This is in contrast to the usual LVEF threshold of &le;40 percent in other patients with asymptomatic left ventricular dysfunction. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Threshold for therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We feel that such an approach is premature, since there is no evidence of benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/11\">",
"     11",
"    </a>",
"    ]. However, periodic echocardiographic monitoring for progression is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of patients with asymptomatic LV systolic dysfunction with an ACE inhibitor (or, if not tolerated, an angiotensin II receptor blocker) and probably a beta blocker reduces the rate of progression of ventricular dysfunction, delays the onset of symptomatic HF, and decreases morbid events and mortality. In contrast, there is no evidence that other measures useful in the treatment of symptomatic heart failure, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , or lifestyle modifications, including salt restriction, exercise, or nutritional supplements, are of benefit in these patients.",
"   </p>",
"   <p>",
"    Several groups of patients with asymptomatic left ventricular systolic dysfunction have been identified in whom early pharmacologic intervention may be important:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Postmyocardial infarction",
"     </li>",
"     <li>",
"      Postrevascularization",
"     </li>",
"     <li>",
"      Chronic LV systolic dysfunction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The management of asymptomatic left ventricular systolic dysfunction in these settings will be reviewed here. There are two other conditions, discussed elsewhere, in which medical therapy can improve or preserve left ventricular function: hypertension with left ventricular hypertrophy and aortic regurgitation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Untreated hypertension is an important risk factor for the development of left ventricular hypertrophy, left ventricular dysfunction, and heart failure. Although heart failure in these patients is most often the result of diastolic dysfunction, symptomatic systolic heart failure and asymptomatic left ventricular dysfunction resulting from left ventricular hypertrophy may also occur [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/13\">",
"       13",
"      </a>",
"      ]. Among hypertensive patients who develop left ventricular hypertrophy, angiotensin II receptor blockers, calcium channel blockers, and ACE inhibitors appear to decrease left ventricular mass more rapidly and to a greater extent than beta blockers, thereby reducing diastolic dysfunction (",
"      <a class=\"graphic graphic_figure graphicRef82558 \" href=\"UTD.htm?42/42/43693\">",
"       figure 4",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. However, many of the commonly used agents eventually produce a similar effect. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=see_link\">",
"       \"Clinical implications and treatment of left ventricular hypertrophy in hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In aortic regurgitation, the regurgitant flow of blood produces a chronic increase in left ventricular end-diastolic volume and wall stress. If untreated, left ventricular hypertrophy and systolic dysfunction eventually ensue. By the time symptoms of heart failure occur, many patients have irreversible left ventricular dysfunction. This observation has provided the rationale for early therapy with vasodilators to reduce afterload in asymptomatic patients, although evidence of benefit is inconclusive. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/14/14567?source=see_link\">",
"       \"Vasodilator therapy in severe chronic aortic regurgitation in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Post-MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial infarction (MI) is the leading cause of heart failure in the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15497?source=see_link\">",
"     \"Epidemiology and causes of heart failure\"",
"    </a>",
"    .) Although a large MI may result in the early appearance of heart failure, symptoms of heart failure usually do not appear for several months to years after the MI. In the interval between infarction and the development of heart failure, there is progressive left ventricular remodeling, which results in cavity dilation and contractile dysfunction. This process begins with myocyte necrosis and formation of a fibrotic scar in the infarcted region, followed by changes in the shape and function of the",
"    <strong>",
"     noninfarcted",
"    </strong>",
"    region [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/52/842?source=see_link\">",
"     \"Cardiac remodeling: Clinical assessment and therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The net effect of this remodeling process is an increase in ventricular cavity volume in excess of ventricular mass, leading to a fall in LVEF, which is typically identified and quantified by noninvasive testing (eg, echocardiography). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=see_link\">",
"     \"Noninvasive methods for measurement of left ventricular systolic function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Current therapeutic approaches to preserving myocardial function following an acute MI are aimed at increasing coronary artery patency and reducing the initial infarct size with the early use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and reperfusion therapy (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5930?source=see_link\">",
"     \"Coronary artery patency and outcome after myocardial infarction\"",
"    </a>",
"    ), and at preventing or slowing remodeling and the late loss of myocardial function with ACE inhibitors and possibly beta blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. These therapies are also associated with improved survival [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/1,22-26\">",
"     1,22-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two large clinical trials, SAVE and TRACE, showed that long-term treatment with ACE inhibitors in patients with asymptomatic left ventricular systolic dysfunction soon after MI delays the onset of symptomatic heart failure and may improve survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the SAVE trial of 2231 asymptomatic patients with an LVEF &le;40 percent after MI,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    therapy (12.5 mg TID increasing to a final target dose of 50 mg TID), starting three to sixteen days after the MI, was associated with the following significant benefits compared to placebo after an average follow-up of 42 months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 19 percent (95 percent confidence interval [CI] 3 to 32 percent) reduction in total mortality (20 versus 25 percent) (",
"      <a class=\"graphic graphic_figure graphicRef66197 \" href=\"UTD.htm?21/60/22477\">",
"       figure 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A 21 percent reduction in cardiovascular mortality",
"     </li>",
"     <li>",
"      A 37 percent (95% CI 20 to 50 percent) decrease in the risk of developing heart failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These benefits were noted in all patient groups including those who received other adjunctive therapies such as thrombolysis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    beta blockers.",
"   </p>",
"   <p>",
"    The TRACE trial randomly assigned 1749 patients with an acute MI associated with an LVEF &le;35 percent to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/41/12952?source=see_link\">",
"     trandolapril",
"    </a>",
"    (titrated to a dose of 4",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo three to seven days after the event; 41 percent of the patients had no symptoms of heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/23\">",
"     23",
"    </a>",
"    ]. After a two to four year follow-up, trandolapril significantly reduced total mortality (by 22 percent), sudden death (by 24 percent), and progression to severe heart failure (by 29 percent) compared to placebo. The mortality benefit was equivalent in subgroups of patients who were asymptomatic. At a minimum follow-up of six years, patients receiving trandolapril had a life expectancy of 6.2 years versus 4.6 years for placebo (",
"    <a class=\"graphic graphic_figure graphicRef81385 \" href=\"UTD.htm?26/24/27022\">",
"     figure 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are conflicting data as to whether ACE inhibitors reduce the incidence of recurrent MI in these patients. The SAVE trial noted a significant 25 percent reduction in recurrent MI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/22\">",
"     22",
"    </a>",
"    ], a finding that was not seen in TRACE [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Acute anterior MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials have evaluated the efficacy of early ACE inhibitor therapy (beginning on the first day) in all patients with an acute anterior MI who are generally at greatest risk for left ventricular dysfunction. The efficacy of this approach appears to depend upon whether reperfusion has been achieved.",
"   </p>",
"   <p>",
"    Early ACE inhibitor therapy (begun within 24 hours of the infarction and continued for six weeks) in patients with anterior MI who were not eligible for thrombolysis was evaluated in the SMILE trial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/28\">",
"     28",
"    </a>",
"    ]. In this trial, 1556 asymptomatic patients were randomly assigned to zofenopril (7.5 mg initial dose and progressively doubled every 12 hours until the target dose of 30 mg twice daily was reached) or placebo. Criteria for exclusion included cardiogenic shock, systolic pressure below 100 mmHg, plasma creatinine concentration above 2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (221",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    a history of heart failure, and current therapy with an ACE inhibitor.",
"   </p>",
"   <p>",
"    The primary six week combined end point, mortality plus severe heart failure, was reduced with zofenopril (7 versus 10.6 percent for placebo; risk reduction 34 percent, 95% CI 8 to 54 percent); this benefit was mainly attributable to less heart failure. At one year, patients receiving zofenopril had a significantly lower mortality rate (10 versus 14 percent; risk reduction 29 percent, 95% CI 6 to 51 percent) (",
"    <a class=\"graphic graphic_figure graphicRef78071 \" href=\"UTD.htm?22/11/22717\">",
"     figure 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The mechanism of early benefit is not clear. Both the cardioprotective effects of ACE inhibition",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prompt blockade of the deleterious effects of neurohumoral activation may contribute. Early administration of ACE inhibitors should be performed only in a carefully monitored setting to permit rapid detection of drug-induced hypotension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13175?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to the above data, there does not appear to be a protective effect of early ACE inhibition in patients with an acute anterior MI who are treated with thrombolytic therapy. In a meta-analysis of three trials involving 845 patients for whom echocardiographic data had been collected, early treatment with an ACE inhibitor did not significantly affect the diastolic or systolic volume index compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/29\">",
"     29",
"    </a>",
"    ]. Subset analysis suggested that left ventricular dilation was significantly attenuated in patients who failed to achieve reperfusion; this group is similar to the patients enrolled in the SMILE trial who were not eligible for thrombolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers are given to most post-MI patients, independent of left ventricular function, because they improve survival and reduce the rate of both sudden death and recurrent MI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=see_link\">",
"     \"Beta blockers in the management of acute coronary syndrome\"",
"    </a>",
"    .) Their specific role, when used alone, for asymptomatic left ventricular dysfunction post-MI, is less clear as controlled trials are lacking. However, possible benefit with beta blockers, when combined with ACE inhibitors, has been suggested by one prospective randomized trial, CAPRICORN, and by a retrospective analysis of the SAVE trial.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the CAPRICORN trial, almost 2000 patients with an LVEF &le;40 percent after an acute MI (the majority of whom were asymptomatic) were treated with an ACE inhibitor and then randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      (6.25",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      initially and then progressively increased during the next four to six weeks to a maximum of 25 mg twice daily) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/24\">",
"       24",
"      </a>",
"      ]. After a mean follow-up of 1.3 years, carvedilol did not reduce the primary end point of combined all-cause mortality and hospitalization for cardiovascular problems (35 versus 37 percent); however, there were significant reductions in all-cause mortality alone (12 versus 15 percent, hazard ratio 0.77, 95% CI 0.60-0.98) and the secondary end point of cardiovascular mortality and nonfatal MI (3 versus 6 percent).",
"     </li>",
"     <li>",
"      In the SAVE trial, 35 percent of patients were treated with a beta blocker at the time of randomization to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      or placebo. After adjustment for baseline difference, beta blocker therapy was associated with a significant 30 percent reduction in the risk of cardiovascular death at one year (13 versus 22 percent for those not on a beta blocker) and a significant 21 percent decrease in the development of heart failure (17 versus 23 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers combined with ACE inhibitors are likely to be beneficial in elderly patients with asymptomatic left ventricular dysfunction, yet they are more likely not to receive either drug than younger patients. Although there are no controlled data addressing this issue, a retrospective analysis of almost 21,000 elderly patients with left ventricular dysfunction after an MI suggested a benefit from combined therapy compared to either drug alone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no studies that directly address the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , diuretics, nitrates, or calcium channel blockers in the management of patients with asymptomatic left ventricular dysfunction due to ischemic cardiomyopathy.",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    improves symptoms in many patients with overt heart failure, there is no evidence that it enhances survival in symptomatic or asymptomatic left ventricular dysfunction. This was best illustrated in the DIG trial in which there was no effect of digoxin on total mortality (",
"    <a class=\"graphic graphic_figure graphicRef80297 \" href=\"UTD.htm?30/9/30877\">",
"     figure 8",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/31\">",
"     31",
"    </a>",
"    ]. Although there was an insignificant trend for a reduction in death from worsening heart failure, this was counterbalanced by an apparent increase in arrhythmic death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=see_link\">",
"     \"Use of digoxin in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no evidence of benefit from calcium channel blockers in patients with asymptomatic heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30438?source=see_link\">",
"     \"Calcium channel blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Postrevascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the prognosis of patients with coronary artery disease and reduced left ventricular function is improved with revascularization, their outcome is worse than in patients who have normal left ventricular function. This suggests a potential benefit from ACE inhibitors in this setting.",
"   </p>",
"   <p>",
"    This issue was examined in the APRES trial of 159 patients with chronic stable angina, an LVEF between 30 and 50 percent, and no clinical heart failure who underwent bypass surgery or angioplasty and were then randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/32\">",
"     32",
"    </a>",
"    ]. After a 33 month follow-up, ramipril significantly reduced the composite end point of cardiac death, acute MI, or clinical heart failure (10 versus 23 percent, risk reduction 58 percent, 95% CI 7 to 80 percent) (",
"    <a class=\"graphic graphic_figure graphicRef53107 \" href=\"UTD.htm?12/45/13021\">",
"     figure 9",
"    </a>",
"    ). The benefit of ramipril was independent of the LVEF and whether bypass surgery or angioplasty was performed but was related, in part, to a reduction in left ventricular end-diastolic and end-systolic volume indices [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Chronic LV systolic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors and possibly beta blockers also appear to be beneficial in patients with asymptomatic chronic left ventricular systolic dysfunction who are not post-MI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A benefit from ACE inhibitors has been noted in both the SOLVD prevention trial and the much smaller Munich Mild Heart Failure trial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/1,34,35\">",
"     1,34,35",
"    </a>",
"    ]. The SOLVD prevention trial consisted of 4228 asymptomatic patients (83 percent had had an MI more than 30 days from entry) with an LVEF &le;35 percent; the patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    (20 mg once per day) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/1\">",
"     1",
"    </a>",
"    ]. At a mean follow-up of just over three years, enalapril therapy was associated with a nonsignificant reduction in cardiovascular mortality compared to placebo (14 versus 16 percent) and a significant 29 percent reduction (95% CI 21 to 36 percent) in the combined incidence of symptomatic heart failure or cardiovascular death (",
"    <a class=\"graphic graphic_figure graphicRef75136 \" href=\"UTD.htm?11/15/11517\">",
"     figure 10",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A subsequent analysis, called XSOLVD, evaluated virtually all of the original participants in the SOLVD prevention trial at a median of 11 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/34\">",
"     34",
"    </a>",
"    ]. The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    group had significant reductions in all-cause mortality (51 versus 56 percent for placebo) and cardiovascular mortality (37 versus 42 percent). No data were available on post-trial drug use.",
"   </p>",
"   <p>",
"    There are no large-scale trials that have specifically evaluated ACE inhibitors in patients with asymptomatic left ventricular dysfunction due to idiopathic dilated cardiomyopathy (IDC). The SOLVD prevention and Munich trials included a small number of such patients. Sufficient benefits were observed in the SOLVD prevention trial to be able to justify the use of ACE inhibitors in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials that have specifically evaluated the effect of beta blockers on cardiovascular outcomes in patients with asymptomatic LV dysfunction who are not post-MI. In the REVERT trial of 149 asymptomatic patients with an LVEF &lt;40 percent who were randomly assigned to treatment with either 200 or 50 mg of extended release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    or placebo, an increase in LVEF was observed in both beta blocker groups as compared to placebo (6 and 4 versus 0 percent at 12 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/36\">",
"     36",
"    </a>",
"    ]. However, clinical outcomes were not evaluated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/52/842?source=see_link&amp;anchor=H17#H17\">",
"     \"Cardiac remodeling: Clinical assessment and therapy\", section on 'Beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The SOLVD prevention trial provided indirect evidence of clinical benefit from beta blocker therapy, similar to that described above in post-MI patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/26\">",
"     26",
"    </a>",
"    ]. Among the patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    , the 24 percent who also received a beta blocker had a significant independent reduction in the risk of death (relative risk 0.70, 95% CI 0.52-0.95) and in death or hospitalization for symptomatic heart failure (relative risk 0.64, 95% CI 0.49-0.83) compared to those using enalapril alone. The mortality benefit with beta blocker therapy was due to a reduction in arrhythmic and pump failure deaths and was not seen in patients assigned to placebo rather than enalapril.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Influence of gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of ACE inhibitor trials suggested that the mortality benefit from ACE inhibitors in patients with asymptomatic left ventricular dysfunction may not apply to women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/37\">",
"     37",
"    </a>",
"    ]. Among trials of ACE inhibitor therapy in asymptomatic LV dysfunction, the relative mortality risk with ACE inhibitor therapy was significantly reduced in men at 0.83 (95% CI 0.71-0.96) but not women at 0.96 (95% CI 0.75-1.22). However, until more definitive data are provided, ACE inhibitors should continue to be used in women with asymptomatic LV dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Influence of race",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SOLVD trials provided information, some of it conflicting, on differences in response to ACE inhibitors between blacks and whites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link&amp;anchor=H8#H8\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\", section on 'Influence of race'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the prevention trial, blacks had higher rates of both progression to heart failure and overall mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a matched-cohort study that included patients from both the prevention and treatment trials,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      therapy produced a significant 44 percent reduction in hospitalization for heart failure compared to placebo; there was no significant reduction among blacks (",
"      <a class=\"graphic graphic_figure graphicRef71327 \" href=\"UTD.htm?27/17/27934\">",
"       figure 11",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other analyses of the SOLVD prevention trial (4054 patients, 403 of whom were black) found that the relative risks of death and of progression to symptomatic heart failure were reduced to the same degree in both blacks and whites [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/37,40\">",
"       37,40",
"      </a>",
"      ]. As in the matched-cohort study, a significant reduction in first hospitalization for HF was seen only in whites (relative risk 0.64 versus 0.85 in blacks) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/40\">",
"       40",
"      </a>",
"      ]. However, this end point was much less frequent than progression to symptomatic HF and it is therefore uncertain if the difference in response was real.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, the role of ACE inhibitors in the treatment of asymptomatic LV dysfunction is the same in blacks as in whites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ARRHYTHMIA MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with certain arrhythmias can develop a tachycardia-mediated cardiomyopathy, in which the tachycardia results in the development of left ventricular dysfunction or the precipitation of heart failure in those with preexisting asymptomatic left ventricular dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=see_link\">",
"     \"Tachycardia-mediated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of tachyarrhythmias have been associated with tachycardia-mediated cardiomyopathy; among patients with an IDC, the most common are atrial fibrillation and atrial flutter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14615?source=see_link\">",
"     \"Pathogenesis of ventricular arrhythmias in heart failure and cardiomyopathy\"",
"    </a>",
"    .) Regardless of the type of arrhythmia, reversion to sinus rhythm or slowing the ventricular rate results in an improvement in left ventricular function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic intervention in the management of patients with asymptomatic left ventricular dysfunction may delay the onset of symptomatic disease, reduce the cardiac event rate, and improve survival. We agree with the recommendations of the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    task force on the management of heart failure that patients with asymptomatic left ventricular systolic dysfunction should treated with an ACE inhibitor and beta blocker (",
"    <a class=\"graphic graphic_table graphicRef67792 \" href=\"UTD.htm?40/15/41212\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/10\">",
"     10",
"    </a>",
"    ]. The 2008 European Society of Cardiology (ESC) guidelines also recommended ACE inhibitors, but recommended beta blockers only in patients who have had a myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , salt restriction beyond that which is prudent for healthy individuals, exercise conditioning, and routine administration of nutritional supplements were",
"    <strong>",
"     NOT",
"    </strong>",
"    recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Threshold for therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    task force did not specify a threshold for \"reduced ejection fraction\" [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/10\">",
"     10",
"    </a>",
"    ]. In randomized trials cited above, such as SOLVD, SAVE, TRACE, and CAPRICORN, the LVEF was &le;35 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/1,22-24\">",
"     1,22-24",
"    </a>",
"    ]. The 2008 guidelines from the ESC defined an LVEF &le;40 as the threshold for therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/41\">",
"     41",
"    </a>",
"    ]. We initiate therapy in appropriate patients when the LVEF is &le;40 percent. Some a suggested a higher threshold in asymptomatic relatives of patients with idiopathic dilated cardiomyopathy. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Familial disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Post-MI or revascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients at high risk for the development of symptomatic heart failure after myocardial infarction or revascularization should receive an ACE inhibitor and beta blocker. As described above, two such groups have been identified: those with asymptomatic left ventricular dysfunction (as defined by an LVEF &le;40 percent); and those with an acute anterior wall infarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The greatest number of lives saved per number treated with an ACE inhibitor has been demonstrated in high-risk patients with impaired left ventricular function",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an anterior MI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/1,22,28,32\">",
"     1,22,28,32",
"    </a>",
"    ]. However, demonstration of asymptomatic left ventricular dysfunction requires bedside imaging studies, and selection of patients by infarct location alone may not result in early identification of all patients with significant left ventricular dysfunction.",
"   </p>",
"   <p>",
"    Thus, unless the infarct is known to be small, it may be most reasonable to consider initial administration of ACE inhibitors in a nonselective fashion (ie, in all patients with an acute MI) and then withdraw therapy later based upon the absence of high-risk features.",
"   </p>",
"   <p>",
"    The safe use of ACE inhibitors soon after acute MI requires oral administration at low doses with careful monitoring of the blood pressure; doses are titrated upward as long as the systolic blood pressure is above 90 to 100 mmHg. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13175?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use\"",
"    </a>",
"    .) Recommended regimens include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"       Captopril",
"      </a>",
"      &mdash; initial dose of 6.25 mg, which is increased to a maximum of 50 mg TID",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"       Enalapril",
"      </a>",
"      &mdash; initial dose 2.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      increased up to 20 mg BID",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"       Lisinopril",
"      </a>",
"      &mdash; initial dose 2.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      increased to a maximum of 40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"       Ramipril",
"      </a>",
"      &mdash; initial dose 2.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      increased up to a maximum of 20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the observations of benefit with ACE inhibitors in patients with asymptomatic left ventricular dysfunction, they are underutilized. In one report, only 48 percent of such patients were discharged on an ACE inhibitor and, when prescribed, the dose was inadequate in 67 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of a contraindication, all post-MI patients are treated with beta blockers because of the demonstrated survival benefit. Among patients with asymptomatic left ventricular dysfunction treated with ACE inhibitors, beta blockers appear to reduce mortality and the rate of progression to symptomatic heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Any of the agents without intrinsic sympathomimetic activity can be used, beginning with very low doses.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     Metoprolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    is preferred. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Beta blockers'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Chronic LV systolic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with dilated cardiomyopathy due to coronary disease or idiopathic dilated cardiomyopathy should be treated with an ACE inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/10\">",
"     10",
"    </a>",
"    ], largely based upon the SOLVD prevention trial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/1\">",
"     1",
"    </a>",
"    ]. Although there is not definitive evidence of benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/26\">",
"     26",
"    </a>",
"    ], it is recommended that such patients should also be treated with a beta blocker (",
"    <a class=\"graphic graphic_table graphicRef67792 \" href=\"UTD.htm?40/15/41212\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to screening for familial disease are discussed above. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Familial disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Risk factor modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other patients with heart disease, risk factor modification is important in patients with asymptomatic left ventricular dysfunction, regardless of etiology, in an attempt to reduce the risk of further injury",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    slowing the progression of left ventricular dysfunction. This includes control of hyperlipidemia, diabetes, and hypertension; cessation of smoking; and elimination of alcohol or illicit drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other recommendations from the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    task force included valve replacement or repair for patients with hemodynamically significant regurgitation or stenosis and regular evaluation for the development of the signs or symptoms of heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28601/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/1\">",
"      Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992; 327:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/2\">",
"      Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/3\">",
"      Drazner MH, Rame JE, Dries DL. Third heart sound and elevated jugular venous pressure as markers of the subsequent development of heart failure in patients with asymptomatic left ventricular dysfunction. Am J Med 2003; 114:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/4\">",
"      Rouleau JL, Moy&eacute; LA, de Champlain J, et al. Activation of neurohumoral systems following acute myocardial infarction. Am J Cardiol 1991; 68:80D.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/5\">",
"      Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/6\">",
"      Rouleau JL, Packer M, Moy&eacute; L, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994; 24:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/7\">",
"      Benedict CR, Shelton B, Johnstone DE, et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation 1996; 94:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/8\">",
"      Tsutamoto T, Wada A, Maeda K, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J 1999; 20:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/9\">",
"      McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/10\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/11\">",
"      Mahon NG, Murphy RT, MacRae CA, et al. Echocardiographic evaluation in asymptomatic relatives of patients with dilated cardiomyopathy reveals preclinical disease. Ann Intern Med 2005; 143:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/12\">",
"      Burkett EL, Hershberger RE. Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 2005; 45:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/13\">",
"      Schillaci G, Vaudo G, Pasqualini L, et al. Left ventricular mass and systolic dysfunction in essential hypertension. J Hum Hypertens 2002; 16:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/14\">",
"      Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/15\">",
"      Dahl&ouml;f B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/16\">",
"      Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000; 101:2981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/17\">",
"      Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000; 35:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/18\">",
"      Mitchell GF, Lamas GA, Vaughan DE, Pfeffer MA. Left ventricular remodeling in the year after first anterior myocardial infarction: a quantitative analysis of contractile segment lengths and ventricular shape. J Am Coll Cardiol 1992; 19:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/19\">",
"      Lamas GA, Vaughan DE, Parisi AF, Pfeffer MA. Effects of left ventricular shape and captopril therapy on exercise capacity after anterior wall acute myocardial infarction. Am J Cardiol 1989; 63:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/20\">",
"      Sharpe N, Smith H, Murphy J, et al. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition. Lancet 1991; 337:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/21\">",
"      Doughty RN, Whalley GA, Gamble G, et al. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997; 29:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/22\">",
"      Pfeffer MA, Braunwald E, Moy&eacute; LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/23\">",
"      K&oslash;ber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/24\">",
"      Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/25\">",
"      Vantrimpont P, Rouleau JL, Wun CC, et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol 1997; 29:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/26\">",
"      Exner DV, Dries DL, Waclawiw MA, et al. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1999; 33:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/27\">",
"      Torp-Pedersen C, K&oslash;ber L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 1999; 354:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/28\">",
"      Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995; 332:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/29\">",
"      de Kam PJ, Voors AA, van den Berg MP, et al. Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilation after myocardial infarction in patients receiving thrombolysis: results of a meta-analysis of 845 patients. FAMIS, CAPTIN and CATS Investigators. J Am Coll Cardiol 2000; 36:2047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/30\">",
"      Shlipak MG, Browner WS, Noguchi H, et al. Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction. Am J Med 2001; 110:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/31\">",
"      The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997; 336:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/32\">",
"      Kj&oslash;ller-Hansen L, Steffensen R, Grande P. The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES). J Am Coll Cardiol 2000; 35:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/33\">",
"      Kj&oslash;ller-Hansen L, Steffensen R, Grande P. Beneficial effects of ramipril on left ventricular end-diastolic and end-systolic volume indexes after uncomplicated invasive revascularization are associated with a reduction in cardiac events in patients with moderately impaired left ventricular function and no clinical heart failure. J Am Coll Cardiol 2001; 37:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/34\">",
"      Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003; 361:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/35\">",
"      Kleber FX, Niem&ouml;ller L, Doering W. Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich Mild Heart Failure Trial. Br Heart J 1992; 67:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/36\">",
"      Colucci WS, Kolias TJ, Adams KF, et al. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. Circulation 2007; 116:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/37\">",
"      Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/38\">",
"      Dries DL, Exner DV, Gersh BJ, et al. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999; 340:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/39\">",
"      Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001; 344:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/40\">",
"      Dries DL, Strong MH, Cooper RS, Drazner MH. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol 2002; 40:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/41\">",
"      Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28601/abstract/42\">",
"      Kermani M, Dua A, Gradman AH. Underutilization and clinical benefits of angiotensin-converting enzyme inhibitors in patients with asymptomatic left ventricular dysfunction. Am J Cardiol 2000; 86:644.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3509 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-194.187.108.93-69C8FD1B77-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_59_28601=[""].join("\n");
var outline_f27_59_28601=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Neurohumoral activation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Familial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Post-MI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Acute anterior MI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Elderly",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Postrevascularization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Chronic LV systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Influence of gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Influence of race",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ARRHYTHMIA MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Threshold for therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Post-MI or revascularization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Chronic LV systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Risk factor modification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3509\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3509|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/60/29645\" title=\"figure 1\">",
"      Survival in asymptomatic LVD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/13/20701\" title=\"figure 2\">",
"      ANP BNP LV dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/33/14878\" title=\"figure 3\">",
"      Plasma NEP asx LV dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/42/43693\" title=\"figure 4\">",
"      Regression of LV hypertrophy with antihypertensive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/60/22477\" title=\"figure 5\">",
"      Captopril lowers cardiovascular mortality post-MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/24/27022\" title=\"figure 6\">",
"      Trandolapril lowers mortality after MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/11/22717\" title=\"figure 7\">",
"      Zofenopril in anterior MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/9/30877\" title=\"figure 8\">",
"      Digoxin and total mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/45/13021\" title=\"figure 9\">",
"      Ramipril post revascularization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/15/11517\" title=\"figure 10\">",
"      ACE inhibitor in LV dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/17/27934\" title=\"figure 11\">",
"      ACEIs in HF in blacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3509|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/15/41212\" title=\"table 1\">",
"      ACC AHA Rx asym LV dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13175?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30438?source=related_link\">",
"      Calcium channel blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/842?source=related_link\">",
"      Cardiac remodeling: Clinical assessment and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=related_link\">",
"      Clinical implications and treatment of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5930?source=related_link\">",
"      Coronary artery patency and outcome after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15497?source=related_link\">",
"      Epidemiology and causes of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=related_link\">",
"      Evaluation of the patient with heart failure or cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/59/5047?source=related_link\">",
"      Familial dilated cardiomyopathy: Prevalence, diagnosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=related_link\">",
"      Noninvasive methods for measurement of left ventricular systolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14615?source=related_link\">",
"      Pathogenesis of ventricular arrhythmias in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32455?source=related_link\">",
"      Pathophysiology of heart failure: Neurohumoral adaptations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=related_link\">",
"      Predictors of survival in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20679?source=related_link\">",
"      Screening for asymptomatic left ventricular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=related_link\">",
"      Tachycardia-mediated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=related_link\">",
"      Use of digoxin in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/14/14567?source=related_link\">",
"      Vasodilator therapy in severe chronic aortic regurgitation in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_59_28602="Atrial fibrillation and flutter after cardiac surgery";
var content_f27_59_28602=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Atrial fibrillation and flutter after cardiac surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/59/28602/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/59/28602/contributors\">",
"     David B Bharucha, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/59/28602/contributors\">",
"     John Michael Stulak, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/59/28602/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/59/28602/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/59/28602/contributors\">",
"     Gabriel S Aldea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/59/28602/contributors\">",
"     Arie Pieter Kappetein, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/59/28602/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/59/28602/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/59/28602/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation (AF) and atrial flutter occur frequently after cardiac surgery. The development of these atrial arrhythmias prolongs hospital stay and is associated with worse long-term prognosis. Other supraventricular arrhythmias, including atrial arrhythmias such as atrioventricular nodal re-entrant tachycardia, are not common in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=see_link\">",
"     \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the pathogenesis, predictors, clinical course, prevention, and management of AF and atrial flutter occurring after cardiac surgery. Most of the observations on atrial arrhythmias come from patients who developed atrial fibrillation. Our approach to patients with atrial flutter is similar, unless otherwise specified.",
"   </p>",
"   <p>",
"    Ventricular tachyarrhythmias after cardiac surgery and arrhythmias after cardiac transplantation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39368?source=see_link&amp;anchor=H13#H13\">",
"     \"Early cardiac complications of coronary artery bypass graft surgery\", section on 'Ventricular tachyarrhythmias'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23576?source=see_link\">",
"     \"Arrhythmias following cardiac transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation and atrial flutter can occur early in the postoperative period or as a late complication of cardiac surgery. A discussion of the mechanisms of AF in the general population is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12266?source=see_link\">",
"     \"Mechanisms of atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postoperative AF is likely related to a combination of factors. These include pre-existing degenerative changes in the atrial myocardium and perioperative conditions that result in abnormalities of several electrophysiologic parameters that promote the development of AF, such as dispersion of atrial refractoriness, increase in phase 3 depolarization, enhanced automaticity, increased interatrial conduction time, and decreased conduction velocity and atrial transmembrane potentials [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=see_link\">",
"     \"The electrocardiogram in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Perioperative factors that have been implicated in the creation of atrial susceptibility to AF or atrial flutter include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pericarditis",
"     </li>",
"     <li>",
"      Atrial injury from surgical handling, or cannulation, atrial suture lines",
"     </li>",
"     <li>",
"      Acute atrial enlargement from pressure or volume overload",
"     </li>",
"     <li>",
"      Inadequate myocardial protection during cardiopulmonary bypass",
"     </li>",
"     <li>",
"      Atrial ischemia",
"     </li>",
"     <li>",
"      Long bypass and aortic cross-clamp times",
"     </li>",
"     <li>",
"      Hyperadrenergic state (eg, use of postoperative inotropic medications)",
"     </li>",
"     <li>",
"      Pulmonary complications, hypoxemia",
"     </li>",
"     <li>",
"      Inflammation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/6,7\">",
"       6,7",
"      </a>",
"      ] (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link&amp;anchor=H26#H26\">",
"       \"Epidemiology of and risk factors for atrial fibrillation\", section on 'Inflammation and infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypokalemia and hypomagnesemia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/8-11\">",
"       8-11",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While mechanisms specific to late AF have not been identified, atrial flutter in these patients is re-entrant and may involve atypical isthmuses between natural barriers, atrial incisions, and scar as well as the cavotricuspid isthmus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients develop AF after cardiac surgery without any apparent predisposing factors. However, most patients have at least one clinical predictor. Preoperative risk factors include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/2,15-26\">",
"     2,15-26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increasing age [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/15-21\">",
"       15-21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Previous history of AF",
"     </li>",
"     <li>",
"      Mitral valvular disease, particularly mitral stenosis",
"     </li>",
"     <li>",
"      Increased left atrial size or cardiomegaly",
"     </li>",
"     <li>",
"      Previous cardiac surgery",
"     </li>",
"     <li>",
"      Chronic obstructive pulmonary disease (COPD)",
"     </li>",
"     <li>",
"      Elevated preoperative hemoglobin A1c [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/27\">",
"       27",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Low-intensity physical activity in the year prior to surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/28\">",
"       28",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Caucasian race [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Obesity [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/26,29\">",
"       26,29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Absence of beta blocker or angiotensin converting enzyme inhibitor (ACE inhibitor) treatment or withdrawal of previous treatment (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Prevention of AF and complications'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Preoperative",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      use in some [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/16,22\">",
"       16,22",
"      </a>",
"      ] but not all studies [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Higher preoperative plasma concentration of brain natriuretic peptide (BNP) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/24\">",
"       24",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"       \"Natriuretic peptide measurement in heart failure\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Low-dose dopamine [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/30\">",
"       30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Severe right coronary artery stenosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Preoperative increase in P wave duration on surface (&gt;116 msec) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/25\">",
"       25",
"      </a>",
"      ] or on signal averaged (&gt;140 msec) ECG (",
"      <a class=\"graphic graphic_figure graphicRef60431 \" href=\"UTD.htm?25/2/25645\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/18,31\">",
"       18,31",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/39/10872?source=see_link\">",
"       \"Use of the signal-averaged electrocardiogram in arrhythmia evaluation and management\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypokalemia and hypomagnesemia (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two potential negative risk factors are off-pump CABG and preservation of the anterior fat pad:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Off-pump CABG ��� OP CABG is associated with a lower rate of postoperative AF than conventional CABG in some [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/32-34\">",
"       32-34",
"      </a>",
"      ], but not all [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/35\">",
"       35",
"      </a>",
"      ], studies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37031?source=see_link\">",
"       \"Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Preservation of the anterior fat pad ��� Some [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/36\">",
"       36",
"      </a>",
"      ], but not all [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/37\">",
"       37",
"      </a>",
"      ], studies have found lower rate of postoperative AF with preservation of the anterior fat pad.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, none of these risk factors has adequate predictive accuracy to identify the individual patient at risk for postoperative atrial arrhythmia. As a result, risk models that use several factors have been created [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/15,38\">",
"     15,38",
"    </a>",
"    ]. In one study, a multivariable risk model was derived in a cohort of 3093 patients, and then tested in a validation cohort of 1564 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/15\">",
"     15",
"    </a>",
"    ]. Predictors were identified for any postoperative AF as well as for recurrent AF. The risk score for any postoperative AF successfully stratified patients into groups at low risk (AF incidence &lt;17 percent), medium risk (AF incidence 17 to 52 percent), and high risk (AF incidence &gt;52 percent) (",
"    <a class=\"graphic graphic_table graphicRef53732 \" href=\"UTD.htm?8/58/9133\">",
"     table 1",
"    </a>",
"    ). While we do not routinely use any of these risk models, they highlight the individual risks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INCIDENCE AND TIME COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation occurs in 15 to 40 percent of patients in the early postoperative period following coronary artery bypass graft surgery (CABG) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/1,15,39,40\">",
"     1,15,39,40",
"    </a>",
"    ], in 37 to 50 percent after valve surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/1,16,17\">",
"     1,16,17",
"    </a>",
"    ], and in as many as 60 percent undergoing valve replacement plus CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/1,16\">",
"     1,16",
"    </a>",
"    ]. The incidence increases with increasing age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/15-21\">",
"     15-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atrial arrhythmias occur most often within the first few days after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/1,15,18,20\">",
"     1,15,18,20",
"    </a>",
"    ]. In a prospective, multicenter study of 4657 patients undergoing surgery, the majority of first episodes of AF occurred by day two, while the majority of recurrent episodes occurred by day three. Forty-three percent of patients with AF had more than one episode [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with postoperative AF who have no prior history of atrial arrhythmias, the AF is usually self-limited, as 15 to 30 percent convert within two hours and up to 80 percent in 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/1,41,42\">",
"     1,41,42",
"    </a>",
"    ]. The mean duration of AF in one report was 11 to 12 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/42\">",
"     42",
"    </a>",
"    ] and more than 90 percent are in sinus rhythm six to eight weeks following surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/1,42-44\">",
"     1,42-44",
"    </a>",
"    ]. In one report, for example, only 3 of 116 patients who developed AF after CABG were still in AF at six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AF may also occur late after cardiac surgery and the incidence is likely higher than appreciated because many patients may have continued asymptomatic episodes of AF. In a study of over 2000 patients enrolled in cardiac rehabilitation programs after cardiac surgery, 11 percent of patients developed AF (4.4 percent new-onset AF) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/45\">",
"     45",
"    </a>",
"    ]. Late postoperative AF was associated with adverse outcomes, including heart failure and rehospitalization.",
"   </p>",
"   <p>",
"    Atrial flutter is relatively uncommon compared to atrial fibrillation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266205047\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of atrial fibrillation or flutter after cardiac surgery may or may not lead to symptoms, such as palpitations, or to a change in the hemodynamic status of the patient. In some individuals with rapid ventricular rates, the blood pressure may fall and potentially be associated with a decline in the urine output.",
"   </p>",
"   <p>",
"    The diagnosis of AF in this setting is usually not difficult as most patients are on continuous monitoring. All patients should have documentation of the rhythm with a 12 lead electrocardiogram. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=see_link\">",
"     \"The electrocardiogram in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ADVERSE OUTCOMES FOLLOWING AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential adverse outcomes after the development of postoperative AF include stroke, death, and prolongation of hospital stay:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postoperative AF has been associated with an increased risk of in-hospital stroke in some [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/16,39,46-50\">",
"       16,39,46-50",
"      </a>",
"      ] but not all series [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]. It is possible that underlying comorbidities, such as older age, cerebrovascular or peripheral artery disease, and cardiopulmonary bypass time, are related to in-hospital stroke rather than the arrhythmia itself [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/48,51-54\">",
"       48,51-54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Postoperative AF may identify a subset of patients with increased in-hospital and long-term mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/7,15,39,40,55,56\">",
"       7,15,39,40,55,56",
"      </a>",
"      ]. This was suggested by a retrospective study of 6475 patients undergoing CABG at a single institution, 994 (15 percent) of whom developed AF [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/39\">",
"       39",
"      </a>",
"      ]. Patients with AF had significantly greater mortality in-hospital (7.4 versus 3.4 percent) and at four years (26 versus 13 percent). In a case-matched subset of 390 patients, the mortality at five years was significantly higher in those with AF (20 versus 7 percent). On multivariate analysis, postoperative AF was a predictor of long-term mortality in both the retrospective cohort (adjusted odds ratio 1.5) and the case-matched population (odds ratio 3.4).",
"      <br/>",
"      <br/>",
"      In another study of 1832 patients who underwent CABG, patients with postoperative AF had a higher long-term mortality (2.99 versus 1.34 per person-years; adjusted hazard ratio 2.13, 95% CI 1.45-3.15) during a median follow-up of 51 months [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/40\">",
"       40",
"      </a>",
"      ]. Patients with AF were at higher risk of dying from systemic embolism (adjusted hazard ratio 4.33, 95% CI 1.78-10.52), but not from other causes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postoperative AF is associated with prolongation of the duration of hospitalization, with an increased length of stay between three and five days in series from the 1990s [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/16,20,46,47\">",
"       16,20,46,47",
"      </a>",
"      ]. However, this effect has become less prominent with current cardiac surgical care [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/57,58\">",
"       57,58",
"      </a>",
"      ]. In a 2008 report of 1832 patients who underwent CABG, the development of AF significantly increased the length of hospital stay by 1.3 days [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PREVENTION OF AF AND COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend therapies to prevent the development of postoperative AF in patients undergoing cardiac surgery in an attempt to decrease the duration of hospitalization, to possibly decrease the risk of in-hospital stroke and death, and to decrease the need for anticoagulation in some patients. Among the available therapies, we prefer beta blockers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H165339032\">",
"    <span class=\"h2\">",
"     Prevention of AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of beta blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , or atrial pacing lowers the risk of postoperative AF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/59\">",
"     59",
"    </a>",
"    ]. Beta blockers are the best studied of these therapies and we prefer beta blockers to sotalol or amiodarone based on their ease of use and better safety profile. We do not recommend atrial pacing in most cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blocker administration is the most widely used prophylactic strategy based on numerous studies showing benefit, ease of use, and cost considerations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/1,15,19,23,57,60-63\">",
"     1,15,19,23,57,60-63",
"    </a>",
"    ]. Meta-analyses of randomized trials from 2002 and 2004 found that they reduced the risk of AF compared to placebo or no therapy (odds ratios of 0.35, 95% CI 0.26-0.49 and 0.39, 95% CI 0.28-0.52) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/57,64\">",
"     57,64",
"    </a>",
"    ]. However, a larger 2006 meta-analysis of 31 trials including 4452 patients performed separate analyses based on whether non-study beta blocker was allowed to be continued or not [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/65\">",
"     65",
"    </a>",
"    ]. When trials confounded by postoperative non-study beta blocker withdrawal were excluded, the effect of beta blockers, although still significant, was less (OR 0.69, 95% CI 0.54-0.87). In addition, other between-trial differences (heterogeneity), such as control group event rates which ranged between 5 and 54 percent, lead us to be unsure of the true magnitude of the benefit from beta blockers in patients who have not previously received them.",
"   </p>",
"   <p>",
"    The benefit is seen when beta blockers are begun prior to or immediately after surgery and, we believe, is independent of the agent or dose used. The optimal duration of therapy for prevention of postoperative atrial arrhythmias is uncertain, but we often continue the beta blocker until the first postoperative visit. However, many patients who undergo CABG have a clear indication for the long-term use of beta blocker therapy (eg, previous myocardial infarction, left ventricular systolic dysfunction with heart failure, or hypertension).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Sotalol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     Sotalol",
"    </a>",
"    is a class III antiarrhythmic agent that has beta blocking activity. A 2011 meta-analysis of 15 randomized studies of patients undergoing cardiac surgery found that sotalol lowered the risk of AF compared to placebo (relative risk [RR] 0.55, 95% CI 0.45-0.66) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/66\">",
"     66",
"    </a>",
"    ]. Compared to beta blocker, sotalol was more effective (14 versus 23 percent; RR=0.64 [CI, 0.50-0.84]). There was no significant difference in the rates between sotalol and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    . Risks of sotalol include torsade de pointes and bradycardia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=see_link\">",
"     \"Therapeutic use and major side effects of sotalol\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     Sotalol",
"    </a>",
"    is effective when begun 24 to 48 hours before surgery or four hours after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Amiodarone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    lowers the incidence of postoperative AF by about 40 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/57,64,69-74\">",
"     57,64,69-74",
"    </a>",
"    ]. A 2006 meta-analysis of 18 trials that included nearly 3000 patients found that amiodarone lowered the risk of AF or atrial flutter compared to placebo (odds ratio [OR] 0.48, 95% CI 0.40-0.57) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is associated with more adverse cardiac events compared to placebo, including bradycardia requiring temporary pacing (5.7 versus 2 percent), and QT prolongation (1.3 versus 0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"     \"Major side effects of amiodarone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     Metoprolol",
"    </a>",
"    was directly compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    in an equivalence trial of 316 hemodynamically stable patients who underwent CABG or valve surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/75\">",
"     75",
"    </a>",
"    ]. The rates of the development of AF were similar (23.9 and 24.8 percent, respectively).",
"   </p>",
"   <p>",
"    A number of different preoperative regimens of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    have been evaluated. It has been given orally one to seven days before surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/70,71\">",
"     70,71",
"    </a>",
"    ], intravenously immediately after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/72\">",
"     72",
"    </a>",
"    ], or intravenously for 24 hours followed by oral therapy for four days [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/73\">",
"     73",
"    </a>",
"    ]. The efficacy of these different regimens is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study randomly assigned 124 patients to oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      or placebo for a minimum of seven days prior to elective cardiac surgery, continuing the drug until discharge [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/70\">",
"       70",
"      </a>",
"      ]. The mean total dose of amiodarone administered was 4.8 grams over 13 days (600",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for seven days followed by 200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      until discharge). The amiodarone group had a significant reduction in the incidence of postoperative atrial fibrillation (25 versus 53 percent) without any increase in fatal or nonfatal postoperative complications.",
"     </li>",
"     <li>",
"      Other oral regimens that have been effective include those that begin either five days before surgery or one day before surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The efficacy of postoperative intravenous therapy was documented in the ARCH trial in which 300 patients were randomly assigned to 1 gram of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      per day for two days or placebo; therapy was begun immediately after CABG [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/72\">",
"       72",
"      </a>",
"      ]. Amiodarone significantly reduced the incidence of atrial fibrillation (35 versus 47 percent for placebo), but did not lower the length of hospitalization (7.6 versus 8.2 days). In another report, intravenous amiodarone begun on call to the operating room and continued for 48 hours, followed by oral amiodarone for three days, also significantly reduced postoperative atrial fibrillation (6 versus 26 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although some have suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    might be more effective than a beta blocker for the prevention of atrial fibrillation after cardiac surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/77\">",
"     77",
"    </a>",
"    ], this was not confirmed in two meta-analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/57,64\">",
"     57,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H165339288\">",
"    <span class=\"h3\">",
"     Atrial pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial pacing to prevent postoperative AF has been examined in a number of studies. Most [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/78-82\">",
"     78-82",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/73,83,84\">",
"     73,83,84",
"    </a>",
"    ], showed benefit. In a 2006 meta-analysis, pacing was associated with a significant reduction in AF (OR 0.60, 95% CI 0.47-0.77) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/65\">",
"     65",
"    </a>",
"    ]. With regard to the optimal pacing strategy (eg, left compared to right atrium or pacing from one or both atria), studies are not definitive [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/79-84\">",
"     79-84",
"    </a>",
"    ]. Atrial pacing is not considered an invasive procedure in these patients because placement of temporary pacing wires is routinely done at the time of surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97330379\">",
"    <span class=\"h3\">",
"     Ineffective or possibly effective therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not recommend any of the following preventative strategies to prevent the development of atrial arrhythmias:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       Digoxin",
"      </a>",
"      ��� Digoxin, given preoperatively or postoperatively, does not appear to prevent AF [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/23,61,62,85\">",
"       23,61,62,85",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Antiarrhythmic drugs",
"      </strong>",
"      ��� Data about the prophylactic use of class I antiarrhythmic drugs to prevent postoperative AF are limited.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       Procainamide",
"      </a>",
"      appears to reduce the number of episodes and duration of AF compared to placebo, but not the incidence of AF [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/86,87\">",
"       86,87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Calcium channel blockers",
"      </strong>",
"      ��� Calcium channel blockers have uncertain utility in preventing AF after cardiac surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/61,88-91\">",
"       61,88-91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Hypomagnesemia",
"      </strong>",
"      ��� Based on the fact that hypomagnesia is a risk factor for AF (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Risk factors'",
"      </a>",
"      above), magnesium supplementation has been evaluated as a possible therapy to reduce postoperative atrial arrhythmias [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/92-97\">",
"       92-97",
"      </a>",
"      ]. In a 2006 meta-analysis of 22 trials including 2896 patients, supraventricular arrhythmias occurred significantly less often in patients treated with magnesium compared to controls (odds ratio 0.48, 95% CI 40-74) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/65\">",
"       65",
"      </a>",
"      ]. However, there was no effect on hospital stay, perioperative myocardial infarction, or mortality. There was also significant heterogeneity in the size of the effect among trials, and the possibility of publication bias was suggested.",
"     </li>",
"     <li>",
"      <strong>",
"       Angiotensin inhibition",
"      </strong>",
"      ��� Although angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) have not previously been considered a specific therapy in patients with AF, a number of observations suggest benefit in nonsurgical settings. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20503?source=see_link\">",
"       \"ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A significant reduction in the incidence of postoperative AF (20 versus 34 percent) with ACE inhibitors was seen in an observational study of 4657 patients undergoing CABG [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/15\">",
"       15",
"      </a>",
"      ]. However, in a study of 445 patients randomly assigned to placebo,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"       ramipril",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      one week to four days prior to cardiac surgery, there was no significant difference in the rate of AF after surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/98\">",
"       98",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Statins",
"      </strong>",
"      ��� Some studies have shown that statins lower the rate of postoperative AF [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/99\">",
"       99",
"      </a>",
"      ]. A 2012 meta-analysis of 11 randomized trials that compared statin therapy to either placebo or no therapy prior to cardiac surgery (predominantly coronary artery bypass graft surgery) found that such treatment reduced the incidence of postoperative AF (odds ratio 0.40, 95% CI 0.29-0.55), but failed to influence short-term mortality or postoperative stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/100\">",
"       100",
"      </a>",
"      ]. Based upon established benefits of statin therapy in patients with coronary heart disease, all patients should be on a statin prior to elective CABG. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40360?source=see_link&amp;anchor=H13#H13\">",
"       \"Medical therapy to prevent complications after coronary artery bypass graft surgery\", section on 'Statins'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=see_link&amp;anchor=H31#H31\">",
"       \"Long-term outcome after coronary artery bypass graft surgery\", section on 'Lipid lowering'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       N-acetylcysteine",
"      </strong>",
"      ��� N-acetylcysteine (NAC) has the potential to protect against the development of perioperative AF due to its antioxidant and anti-inflammatory properties. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      This hypothesis was tested in a trial of 115 patients undergoing either CABG or valve surgery who were randomly assigned to either NAC or placebo given one hour before and continued for 48 hours after surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/101\">",
"       101",
"      </a>",
"      ]. The primary end point of an AF episode lasting longer than five minutes during hospitalization was seen in 15 patients and was significantly less common in those who received NAC (5.2 versus 21.2 percent).",
"      <br/>",
"      <br/>",
"      In a small study designed to evaluate the potential benefit of anti-inflammatory therapy (with NAC or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      ), 311 patients undergoing cardiac surgery who had no history of AF were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      , carvedilol, or carvedilol plus NAC [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/102\">",
"       102",
"      </a>",
"      ]. The incidence of postoperative AF was significantly lower in the carvedilol plus NAC group compared to either of the other two interventions (35.9, 24.0, and 8.7 percent, respectively).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       Colchicine",
"      </a>",
"      ��� Colchicine reduced the incidence of the postpericardiotomy syndrome in the COPPS trial. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/44/713?source=see_link&amp;anchor=H12602686#H12602686\">",
"       \"Treatment of acute pericarditis\", section on 'Colchicine'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The issue of whether colchicine can reduce the incidence of postoperative AF was addressed in a post hoc substudy. In COPPS, 360 patients undergoing cardiac surgery were randomly assigned to either colchicine 1.0 mg given twice daily on day one followed by 0.5 mg twice daily for one month (the dose was halved in patients &lt;70 kg) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/103\">",
"       103",
"      </a>",
"      ]. The first dose was given on postoperative day three. The COPPS Prevention of Atrial Fibrillation (POAF) substudy evaluated outcomes in the 336 patients in sinus rhythm on day three.",
"      <br/>",
"      <br/>",
"      Colchicine significantly reduced the incidence of postoperative AF (12 versus 22 percent; relative risk reduction 45.5 percent, 95% CI 34.0-94.0 percent) at 30 days. In addition, patients taking colchicine had a significantly shorter in-hospital stay (9.4 versus 10.3 days). There was a trend toward a higher rate of side effects (9.5 versus 4.8 percent) and drug withdrawal (11.8 versus 6.6 percent) with colchicine, but no severe side effects were recorded.",
"      <br/>",
"      <br/>",
"      We believe there is insufficient evidence to recommend the routine use of colchicine, in part out of a concern that it may negatively impact wound healing.",
"     </li>",
"     <li>",
"      <strong>",
"       Fish oil",
"      </strong>",
"      ��� The potential role of fish oil to reduce the incidence of postoperative AF after CABG is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=see_link&amp;anchor=H20#H20\">",
"       \"Fish oil and marine omega-3 fatty acids\", section on 'Atrial fibrillation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Antioxidant vitamins",
"      </strong>",
"      ��� A 2011 meta-analysis evaluating five randomized trials comprising 567 patients found that the prophylactic use of vitamins C and E lowered the rate of postoperative AF (odds ratio 0.43, 95% CI 0.21-0.89) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/104\">",
"       104",
"      </a>",
"      ]. The conclusion of the meta-analysis is limited by the inclusion of small, low-quality studies.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       Naproxen",
"      </a>",
"      ��� The potential benefit from naproxen was evaluated in the NAFARM trial, which randomly assigned 161 patients to either naproxen or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/105\">",
"       105",
"      </a>",
"      ]. There was no significant difference in the rate of postoperative AF (7 versus 15 percent, respectively). The study was stopped early because of an increase in renal failure in the naproxen group.",
"     </li>",
"     <li>",
"      <strong>",
"       Glucocorticoid",
"      </strong>",
"      ��� Based upon the hypothesis that perioperative inflammation may contribute to the development of AF, glucocorticoids have been suggested as prophylactic therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28249?source=see_link\">",
"       \"Glucocorticoid effects on the immune system\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Two meta-analyses in which glucocorticoid treatment was compared to placebo or no treatment in adult cardiac surgery found 26 and 40 percent reductions in the incidence of AF, irrespective of the dose given [",
"      <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/106,107\">",
"       106,107",
"      </a>",
"      ]. Due to their potential adverse effects on glucose metabolism, wound healing, and infection, additional data on both the efficacy and safety of this approach are necessary, prior to our recommending such therapy.",
"      <br/>",
"      <br/>",
"      The potential role for glucocorticoid therapy for other outcomes is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40360?source=see_link&amp;anchor=H14#H14\">",
"       \"Medical therapy to prevent complications after coronary artery bypass graft surgery\", section on 'Glucocorticoid therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H423952309\">",
"    <span class=\"h2\">",
"     Prevention of complications of AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;While beta blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , and pacing decrease the risk of postoperative AF, the evidence is less robust that the risk of complications such as stroke, death, or length of stay can be prevented. It may be difficult to demonstrate a lowering of the risk of in-hospital stroke with these therapies, as AF is only one risk factor for stroke and as the incidence of stroke is low. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Adverse outcomes following AF'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The best available evidence of the impact of these interventions on the complications of AF comes from a 2006 meta-analysis of heterogenous trials, which noted the following [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/65\">",
"     65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 29 trials that evaluated length of stay, only",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      and pacing shortened the average length of stay (-0.60 days, 95% CI -0.92 to -0.29 and -1.3 days 95% CI -2.55 to -0.08, respectively).",
"     </li>",
"     <li>",
"      In 25 trials that reported on the incidence of postoperative stroke, the risk of stroke was decreased from 1.9 to 1.1 percent with treatment (odds ratio 0.63, 95% CI 0.41-0.98).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      was the only single intervention that significantly lowered the risk of stroke compared to placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another benefit from the prevention of AF is that the need for anticoagulation and its associated burden and risks can be avoided in some patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link\">",
"     \"Therapeutic use of warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H423952316\">",
"    <span class=\"h2\">",
"     Our approach to prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend preventative therapy to reduce the incidence of postoperative AF, especially in patients at high risk of its development. While the evidence is not robust, prevention of AF may lead to a lowering of the risk of in-hospital stroke and a shortened length of stay. In addition, successful prevention of AF will prevent the need for anticoagulation in some patients. Beta blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , or pacing are significantly more effective than placebo in lowering the rate of postoperative AF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/57,64,65\">",
"     57,64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We prefer beta blockers to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    due to lower cost and lower risk of potential side effects and to pacing because of its relative complexity and cost. Amiodarone or sotalol is a reasonable alternative in patients who cannot tolerate beta blockade.",
"   </p>",
"   <p>",
"    If possible, we prefer to start beta blockers prior to CABG. We suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    25 mg twice daily; the dose can be titrated postoperative based on the heart rate and blood pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;While prevention with beta blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , or pacing lowers the risk of postoperative AF, many patients still develop AF (see",
"    <a class=\"local\" href=\"#H165339032\">",
"     'Prevention of AF'",
"    </a>",
"    above). We are uncertain as to the optimal management of these patients, in part because it is not known whether postoperative AF represents the same arrhythmia as AF occurring without cardiac surgery or if it possesses a similar natural history in terms of portending adverse events.",
"   </p>",
"   <p>",
"    We think the initial management should include correction of predisposing factors such as hypoxemia, electrolyte abnormalities, and hemodynamic instability as well as pain management and withdrawal of stimulating factors such as inotropic agents. Subsequent management relates to the issues of rate control, cardioversion, and anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Rate control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the transient nature of the arrhythmia, initial control of the ventricular response rate is an effective and relatively safe strategy, compared to early cardioversion, in patients who develop postoperative AF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/41,109\">",
"     41,109",
"    </a>",
"    ]. Rate control seems to be as effective as cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In a randomized trial of 50 patients, there was no difference between the two strategies in the time to restoration of sinus rhythm (11.8 versus 11.2 hours for reversion), the AF relapse rate at one, four, or eight weeks, or the proportion of patients in sinus rhythm at two months (91 versus 96 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rate control is most commonly achieved with beta blockers. The benefit is partly due to blockade of the augmented postoperative sympathetic state and to prevention of beta blocker withdrawal in patients on beta blockers preoperatively. Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"     esmolol",
"    </a>",
"    , a beta blocker with a short half-life, can be given for acute rate control if there is a concern for bradyarrhythmias, hypotension, or bronchospasm.",
"   </p>",
"   <p>",
"    The optimal rate goal for patients with AF after cardiac surgery has not been determined. As these patients vary widely in many clinical features (co-morbidities, need for rapid ventricular rate, etc), we suggest that the optimal ventricular rate be determined on a case by case basis. In many patients, a ventricular rate of less than 110 beats per minute will prevent symptoms such as palpitations and allow for optimal cardiac performance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link&amp;anchor=H4#H4\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\", section on 'Rate control goals'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Calcium channel blockers and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    are other atrioventricular (AV) nodal blockers that can control the ventricular rate in AF, but they are not more effective than beta blockers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Cardioversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardioversion from well tolerated postoperative AF is usually not necessary because of the high early recurrence rate and the eventual self-limited course. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Incidence and time course'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Cardioversion may be indicated in highly symptomatic patients or in those when rate control is difficult to achieve. In addition, cardioversion in asymptomatic patients may be reasonable when well tolerated AF occurs near the time of anticipated hospital discharge or when it does not spontaneously terminate within 24 hours, so that oral anticoagulation can be avoided. We believe that an attempt at cardioversion with either electrical or pharmacologic therapy is reasonable. The choice between the two should be made on local practice and patient conditions.",
"   </p>",
"   <p>",
"    Electrical therapy of AF involves direct current external transthoracic cardioversion and it is effective in approximately 95 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/110\">",
"     110",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=see_link\">",
"     \"Cardioversion for specific arrhythmias\"",
"    </a>",
"    ). For patients who are refractory to transthoracic cardioversion or when reversion is desirable but the patient's respiratory status makes anesthesia for electrical conversion potentially difficult, pharmacologic therapy with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is reasonable. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Sotalol'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H17\">",
"     'Amiodarone'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The efficacy of antiarrhythmic drugs for reversion of postoperative AF is similar to that in AF not related to surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/111-119\">",
"     111-119",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53913896\">",
"    <span class=\"h3\">",
"     Patients on long-term anticoagulant",
"    </span>",
"    &nbsp;&mdash;&nbsp;For AF patients who are taking long-term oral anticoagulation, we suggest stopping this therapy at least three days before surgery. We restart oral anticoagulant therapy three to five days after surgery. The role of bridging",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy for patients at high risk of an embolic complication while off oral anticoagulant, such as those with AF and a prior embolic event, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link&amp;anchor=H2441429#H2441429\">",
"     \"Management of anticoagulation before and after elective surgery\", section on 'Bridging anticoagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53914044\">",
"    <span class=\"h3\">",
"     Patients not taking anticoagulant prior to cardiac surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AF or atrial flutter, regardless of the setting, are at risk for thromboembolic events; the magnitude of that risk varies based upon a number of factors. Thromboembolic risk is primarily limited to AF or atrial flutter of more than 48 hours duration and is greater in patients with certain high risk features (eg, rheumatic mitral valve disease, previous thromboembolism, hypertension, or heart failure) (",
"    <a class=\"graphic graphic_table graphicRef61615 \" href=\"UTD.htm?39/45/40668\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/108\">",
"     108",
"    </a>",
"    ]. The general recommendations for anticoagulation in patients with AF are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37511?source=see_link\">",
"     \"Embolic risk and the role of anticoagulation in atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who develop AF after cardiac surgery are at risk of thromboembolic events, including in-hospital stroke. However, in the individual post-surgical patient with an embolic event, the cause may be unclear, as underlying comorbidities are often responsible for such strokes, rather than the arrhythmia itself [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/51,57,120\">",
"     51,57,120",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Incidence and time course'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Based on evidence that oral anticoagulant therapy prevents episodes of systemic embolization in the broad population of patients with atrial fibrillation, we believe that such therapy will lead to fewer embolic events in patients with postoperative AF. However, a reduction of events with anticoagulant therapy in this population has never been well studied. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H31#H31\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As factors other than AF contribute to in-hospital stroke rates, it is not clear that aggressive early anticoagulation (eg, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    as a bridge to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ) will reduce the incidence of stroke. In addition, the bleeding risk associated with anticoagulation in the immediate postoperative period (within the first 48 hours in most patients) makes the overall impact of this approach less certain. The potential complications associated with anticoagulation were illustrated in several observational series of patients who were treated with intravenous heparin or oral anticoagulants for a variety of indications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/121-123\">",
"     121-123",
"    </a>",
"    ]. When closely monitored, complication rates appear to be low [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/121,122\">",
"     121,122",
"    </a>",
"    ]. However, one report found a significant increase in large pericardial effusions and tamponade in patients treated with warfarin, particularly when the International normalized ratio (INR) was above the therapeutic target [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/123\">",
"     123",
"    </a>",
"    ]. These large effusions all occurred one week or more after surgery. Thus, when anticoagulation is initiated, the patient must be monitored carefully. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link\">",
"     \"Management of anticoagulation before and after elective surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly, the optimal duration of anticoagulation after hospital discharge is unknown. Among patients with new-onset AF after cardiac surgery, many will revert to and maintain sinus rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/1,42-44\">",
"     1,42-44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Our approach to postoperative anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who develop AF following cardiac surgery, we suggest the following approach to anticoagulation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with multiple episodes of AF or one episode that lasts more than 24 to 48 hours, we recommend the initiation of oral anticoagulant therapy, but only if bleeding risks are considered acceptable. As the role of direct thrombin and factor Xa inhibitors has not been established for patients with postoperative AF, we suggest that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      be chosen for most patients (International normalized ratio 2.0-3.0). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H524842274#H524842274\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Direct thrombin and factor Xa inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest continuation of anticoagulation for four weeks after return to sinus rhythm, particularly if the patient has risk factors for thromboembolism. This applies both to patients who are discharged in AF or those who have been cardioverted or reverted to sinus rhythm. Long-term anticoagulation should be considered for patients who remain in AF or who have paroxysmal AF at four weeks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H31#H31\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most cases, we do not use intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    as a bridge to full oral anticoagulation, as the risk of post-operative bleeding outweighs the small benefit from stroke prevention. For patients with prior systemic or pulmonary embolization or those with a mechanical valve, bridging anticoagulation with heparin may be reasonable.",
"   </p>",
"   <p>",
"    Both intravenous and oral anticoagulation should be monitored closely, as bleeding complications, including pericardial effusion and tamponade increase with excessive anticoagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97331689\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines from the American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association (2011) and the European Society of Cardiology (2006, 2010, 2012) have addressed the issue of postoperative AF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/59/28602/abstract/110,124-126\">",
"     110,124-126",
"    </a>",
"    ]. Our recommendations are generally consistent with recommendations from these groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194220665\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrial fibrillation (AF) and atrial flutter occur frequently after cardiac surgery. Most episodes occur by the third postoperative day. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Incidence and time course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potential adverse outcomes with postoperative AF include a longer length of stay and in-hospital stroke or death. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Adverse outcomes following AF'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Beta blockers,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , and atrial pacing lower the risk of the development of AF and may reduce the length of stay and lower the risk of in-hospital stroke. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Prevention of AF and complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients undergoing cardiac surgery, we recommend preventative therapy to reduce the incidence of postoperative AF (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H423952316\">",
"       'Our approach to prevention'",
"      </a>",
"      above.) This therapy should be started prior to surgery if possible and continued at least until the first post-operative visit.",
"      <br/>",
"      <br/>",
"      We recommend beta blockers rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      For patients who cannot take beta blockers, we recommend amiodarone rather than sotalol (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For hemodynamically stable patients who develop postoperative AF, the optimal ventricular rate range should be determined for each patient. In many patients, this rate will be less than 110 beats per minute. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Rate control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who develop well-tolerated postoperative AF and whose rate is well controlled, we suggest not performing cardioversion within the first 24 hours of its development (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Cardioversion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cardioversion may be required within this time frame for those whose AF is poorly tolerated or whose rate is not well controlled.",
"    <br/>",
"    <br/>",
"    Cardioversion in asymptomatic patients may be reasonable when well-tolerated AF is present near the time of anticipated hospital discharge, or when it does not spontaneously terminate within 24 to 48 hours, so that oral anticoagulation can be avoided.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with multiple episodes of AF or one episode that lasts more than 24 to 48 hours, and if the perioperative bleeding risks are considered reasonable, we recommend oral anticoagulation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H41\">",
"       'Our approach to postoperative anticoagulation'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We suggest anticoagulation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (International normalized ratio 2.0-3.0) rather than either a direct thrombin or factor Xa inhibitor (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      For patients in whom anticoagulation is started and irrespective of the rhythm status at the time of discharge from the hospital, we suggest continuation of anticoagulation for four weeks, rather than stopping (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346699792\">",
"    <span class=\"h1\">",
"     ACKOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. Roger A. Marinchak for his contributions as an author to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/1\">",
"      Maisel WH, Rawn JD, Stevenson WG. Atrial fibrillation after cardiac surgery. Ann Intern Med 2001; 135:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/2\">",
"      Cox JL. A perspective of postoperative atrial fibrillation in cardiac operations. Ann Thorac Surg 1993; 56:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/3\">",
"      Tsikouris JP, Kluger J, Song J, White CM. Changes in P-wave dispersion and P-wave duration after open heart surgery are associated with the peak incidence of atrial fibrillation. Heart Lung 2001; 30:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/4\">",
"      Dupont E, Ko Y, Rothery S, et al. The gap-junctional protein connexin40 is elevated in patients susceptible to postoperative atrial fibrillation. Circulation 2001; 103:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/5\">",
"      Karaca M, Demirbas MI, Biceroglu S, et al. Prediction of early postoperative atrial fibrillation after cardiac surgery: is it possible? Cardiovasc J Afr 2012; 23:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/6\">",
"      Korantzopoulos P, Kolettis TM, Galaris D, Goudevenos JA. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol 2007; 115:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/7\">",
"      Bramer S, van Straten AH, Soliman Hamad MA, et al. The impact of new-onset postoperative atrial fibrillation on mortality after coronary artery bypass grafting. Ann Thorac Surg 2010; 90:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/8\">",
"      Wahr JA, Parks R, Boisvert D, et al. Preoperative serum potassium levels and perioperative outcomes in cardiac surgery patients. Multicenter Study of Perioperative Ischemia Research Group. JAMA 1999; 281:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/9\">",
"      Zaman AG, Alamgir F, Richens T, et al. The role of signal averaged P wave duration and serum magnesium as a combined predictor of atrial fibrillation after elective coronary artery bypass surgery. Heart 1997; 77:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/10\">",
"      Aglio LS, Stanford GG, Maddi R, et al. Hypomagnesemia is common following cardiac surgery. J Cardiothorac Vasc Anesth 1991; 5:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/11\">",
"      Reinhart RA, Marx JJ Jr, Broste SK, Haas RG. Myocardial magnesium: relation to laboratory and clinical variables in patients undergoing cardiac surgery. J Am Coll Cardiol 1991; 17:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/12\">",
"      Verma A, Marrouche NF, Seshadri N, et al. Importance of ablating all potential right atrial flutter circuits in postcardiac surgery patients. J Am Coll Cardiol 2004; 44:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/13\">",
"      Akar JG, Kok LC, Haines DE, et al. Coexistence of type I atrial flutter and intra-atrial re-entrant tachycardia in patients with surgically corrected congenital heart disease. J Am Coll Cardiol 2001; 38:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/14\">",
"      Seiler J, Schmid DK, Irtel TA, et al. Dual-loop circuits in postoperative atrial macro re-entrant tachycardias. Heart 2007; 93:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/15\">",
"      Mathew JP, Fontes ML, Tudor IC, et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004; 291:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/16\">",
"      Creswell LL, Schuessler RB, Rosenbloom M, Cox JL. Hazards of postoperative atrial arrhythmias. Ann Thorac Surg 1993; 56:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/17\">",
"      Asher CR, Miller DP, Grimm RA, et al. Analysis of risk factors for development of atrial fibrillation early after cardiac valvular surgery. Am J Cardiol 1998; 82:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/18\">",
"      Zaman AG, Archbold RA, Helft G, et al. Atrial fibrillation after coronary artery bypass surgery: a model for preoperative risk stratification. Circulation 2000; 101:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/19\">",
"      Pires LA, Wagshal AB, Lancey R, Huang SK. Arrhythmias and conduction disturbances after coronary artery bypass graft surgery: epidemiology, management, and prognosis. Am Heart J 1995; 129:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/20\">",
"      Aranki SF, Shaw DP, Adams DH, et al. Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. Circulation 1996; 94:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/21\">",
"      Mendes LA, Connelly GP, McKenney PA, et al. Right coronary artery stenosis: an independent predictor of atrial fibrillation after coronary artery bypass surgery. J Am Coll Cardiol 1995; 25:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/22\">",
"      Deliargyris EN, Raymond RJ, Guzzo JA, et al. Preoperative factors predisposing to early postoperative atrial fibrillation after isolated coronary artery bypass grafting. Am J Cardiol 2000; 85:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/23\">",
"      Rubin DA, Nieminski KE, Reed GE, Herman MV. Predictors, prevention, and long-term prognosis of atrial fibrillation after coronary artery bypass graft operations. J Thorac Cardiovasc Surg 1987; 94:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/24\">",
"      Wazni OM, Martin DO, Marrouche NF, et al. Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery. Circulation 2004; 110:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/25\">",
"      Buxton AE, Josephson ME. The role of P wave duration as a predictor of postoperative atrial arrhythmias. Chest 1981; 80:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/26\">",
"      Zacharias A, Schwann TA, Riordan CJ, et al. Obesity and risk of new-onset atrial fibrillation after cardiac surgery. Circulation 2005; 112:3247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/27\">",
"      Kinoshita T, Asai T, Suzuki T, et al. Preoperative hemoglobin A1c predicts atrial fibrillation after off-pump coronary bypass surgery. Eur J Cardiothorac Surg 2012; 41:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/28\">",
"      Giaccardi M, Macchi C, Colella A, et al. Postacute rehabilitation after coronary surgery: the effect of preoperative physical activity on the incidence of paroxysmal atrial fibrillation. Am J Phys Med Rehabil 2011; 90:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/29\">",
"      Bramer S, van Straten AH, Soliman Hamad MA, et al. Body mass index predicts new-onset atrial fibrillation after cardiac surgery. Eur J Cardiothorac Surg 2011; 40:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/30\">",
"      Argalious M, Motta P, Khandwala F, et al. \"Renal dose\" dopamine is associated with the risk of new-onset atrial fibrillation after cardiac surgery. Crit Care Med 2005; 33:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/31\">",
"      Steinberg JS, Zelenkofske S, Wong SC, et al. Value of the P-wave signal-averaged ECG for predicting atrial fibrillation after cardiac surgery. Circulation 1993; 88:2618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/32\">",
"      Wijeysundera DN, Beattie WS, Djaiani G, et al. Off-pump coronary artery surgery for reducing mortality and morbidity: meta-analysis of randomized and observational studies. J Am Coll Cardiol 2005; 46:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/33\">",
"      Athanasiou T, Aziz O, Mangoush O, et al. Do off-pump techniques reduce the incidence of postoperative atrial fibrillation in elderly patients undergoing coronary artery bypass grafting? Ann Thorac Surg 2004; 77:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/34\">",
"      Angelini GD, Taylor FC, Reeves BC, Ascione R. Early and midterm outcome after off-pump and on-pump surgery in Beating Heart Against Cardioplegic Arrest Studies (BHACAS 1 and 2): a pooled analysis of two randomised controlled trials. Lancet 2002; 359:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/35\">",
"      Almassi GH, Pecsi SA, Collins JF, et al. Predictors and impact of postoperative atrial fibrillation on patients' outcomes: a report from the Randomized On Versus Off Bypass trial. J Thorac Cardiovasc Surg 2012; 143:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/36\">",
"      Cummings JE, Gill I, Akhrass R, et al. Preservation of the anterior fat pad paradoxically decreases the incidence of postoperative atrial fibrillation in humans. J Am Coll Cardiol 2004; 43:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/37\">",
"      White CM, Sander S, Coleman CI, et al. Impact of epicardial anterior fat pad retention on postcardiothoracic surgery atrial fibrillation incidence: the AFIST-III Study. J Am Coll Cardiol 2007; 49:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/38\">",
"      Amar D, Shi W, Hogue CW Jr, et al. Clinical prediction rule for atrial fibrillation after coronary artery bypass grafting. J Am Coll Cardiol 2004; 44:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/39\">",
"      Villareal RP, Hariharan R, Liu BC, et al. Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J Am Coll Cardiol 2004; 43:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/40\">",
"      Mariscalco G, Klersy C, Zanobini M, et al. Atrial fibrillation after isolated coronary surgery affects late survival. Circulation 2008; 118:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/41\">",
"      Soucier RJ, Mirza S, Abordo MG, et al. Predictors of conversion of atrial fibrillation after cardiac operation in the absence of class I or III antiarrhythmic medications. Ann Thorac Surg 2001; 72:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/42\">",
"      Lee JK, Klein GJ, Krahn AD, et al. Rate-control versus conversion strategy in postoperative atrial fibrillation: a prospective, randomized pilot study. Am Heart J 2000; 140:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/43\">",
"      Kowey PR, Stebbins D, Igidbashian L, et al. Clinical outcome of patients who develop PAF after CABG surgery. Pacing Clin Electrophysiol 2001; 24:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/44\">",
"      Landymore RW, Howell F. Recurrent atrial arrhythmias following treatment for postoperative atrial fibrillation after coronary bypass operations. Eur J Cardiothorac Surg 1991; 5:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/45\">",
"      Ambrosetti M, Tramarin R, Griffo R, et al. Late postoperative atrial fibrillation after cardiac surgery: a national survey within the cardiac rehabilitation setting. J Cardiovasc Med (Hagerstown) 2011; 12:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/46\">",
"      Stamou SC, Dangas G, Hill PC, et al. Atrial fibrillation after beating heart surgery. Am J Cardiol 2000; 86:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/47\">",
"      Almassi GH, Schowalter T, Nicolosi AC, et al. Atrial fibrillation after cardiac surgery: a major morbid event? Ann Surg 1997; 226:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/48\">",
"      Reed GL 3rd, Singer DE, Picard EH, DeSanctis RW. Stroke following coronary-artery bypass surgery. A case-control estimate of the risk from carotid bruits. N Engl J Med 1988; 319:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/49\">",
"      Taylor GJ, Malik SA, Colliver JA, et al. Usefulness of atrial fibrillation as a predictor of stroke after isolated coronary artery bypass grafting. Am J Cardiol 1987; 60:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/50\">",
"      Lahtinen J, Biancari F, Salmela E, et al. Postoperative atrial fibrillation is a major cause of stroke after on-pump coronary artery bypass surgery. Ann Thorac Surg 2004; 77:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/51\">",
"      Hogue CW Jr, Murphy SF, Schechtman KB, D&aacute;vila-Rom&aacute;n VG. Risk factors for early or delayed stroke after cardiac surgery. Circulation 1999; 100:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/52\">",
"      Lotfi A, Wartak S, Sethi P, et al. Postoperative atrial fibrillation is not associated with an increase risk of stroke or the type and number of grafts: a single-center retrospective analysis. Clin Cardiol 2011; 34:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/53\">",
"      Newman MF, Wolman R, Kanchuger M, et al. Multicenter preoperative stroke risk index for patients undergoing coronary artery bypass graft surgery. Multicenter Study of Perioperative Ischemia (McSPI) Research Group. Circulation 1996; 94:II74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/54\">",
"      Mickleborough LL, Walker PM, Takagi Y, et al. Risk factors for stroke in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 1996; 112:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/55\">",
"      Kalavrouziotis D, Buth KJ, Ali IS. The impact of new-onset atrial fibrillation on in-hospital mortality following cardiac surgery. Chest 2007; 131:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/56\">",
"      Saxena A, Dinh DT, Smith JA, et al. Usefulness of postoperative atrial fibrillation as an independent predictor for worse early and late outcomes after isolated coronary artery bypass grafting (multicenter Australian study of 19,497 patients). Am J Cardiol 2012; 109:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/57\">",
"      Crystal E, Garfinkle MS, Connolly SS, et al. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev 2004; :CD003611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/58\">",
"      Kim MH, Deeb GM, Morady F, et al. Effect of postoperative atrial fibrillation on length of stay after cardiac surgery (The Postoperative Atrial Fibrillation in Cardiac Surgery study [PACS(2)]. Am J Cardiol 2001; 87:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/59\">",
"      Arsenault KA, Yusuf AM, Crystal E, et al. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev 2013; 1:CD003611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/60\">",
"      Stephenson LW, MacVaugh H 3rd, Tomasello DN, Josephson ME. Propranolol for prevention of postoperative cardiac arrhythmias: a randomized study. Ann Thorac Surg 1980; 29:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/61\">",
"      Andrews TC, Reimold SC, Berlin JA, Antman EM. Prevention of supraventricular arrhythmias after coronary artery bypass surgery. A meta-analysis of randomized control trials. Circulation 1991; 84:III236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/62\">",
"      Kowey PR, Taylor JE, Rials SJ, Marinchak RA. Meta-analysis of the effectiveness of prophylactic drug therapy in preventing supraventricular arrhythmia early after coronary artery bypass grafting. Am J Cardiol 1992; 69:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/63\">",
"      Khuri SF, Okike ON, Josa M, et al. Efficacy of nadolol in preventing supraventricular tachycardia after coronary artery bypass grafting. Am J Cardiol 1987; 60:51D.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/64\">",
"      Crystal E, Connolly SJ, Sleik K, et al. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation 2002; 106:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/65\">",
"      Burgess DC, Kilborn MJ, Keech AC. Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis. Eur Heart J 2006; 27:2846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/66\">",
"      Kerin NZ, Jacob S. The efficacy of sotalol in preventing postoperative atrial fibrillation: a meta-analysis. Am J Med 2011; 124:875.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/67\">",
"      Gomes JA, Ip J, Santoni-Rugiu F, et al. Oral d,l sotalol reduces the incidence of postoperative atrial fibrillation in coronary artery bypass surgery patients: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1999; 34:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/68\">",
"      Suttorp MJ, Kingma JH, Peels HO, et al. Effectiveness of sotalol in preventing supraventricular tachyarrhythmias shortly after coronary artery bypass grafting. Am J Cardiol 1991; 68:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/69\">",
"      Aasbo JD, Lawrence AT, Krishnan K, et al. Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis. Ann Intern Med 2005; 143:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/70\">",
"      Daoud EG, Strickberger SA, Man KC, et al. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. N Engl J Med 1997; 337:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/71\">",
"      Giri S, White CM, Dunn AB, et al. Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial. Lancet 2001; 357:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/72\">",
"      Guarnieri T, Nolan S, Gottlieb SO, et al. Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: the Amiodarone Reduction in Coronary Heart (ARCH) trial. J Am Coll Cardiol 1999; 34:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/73\">",
"      White CM, Caron MF, Kalus JS, et al. Intravenous plus oral amiodarone, atrial septal pacing, or both strategies to prevent post-cardiothoracic surgery atrial fibrillation: the Atrial Fibrillation Suppression Trial II (AFIST II). Circulation 2003; 108 Suppl 1:II200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/74\">",
"      Mitchell LB, Exner DV, Wyse DG, et al. Prophylactic Oral Amiodarone for the Prevention of Arrhythmias that Begin Early After Revascularization, Valve Replacement, or Repair: PAPABEAR: a randomized controlled trial. JAMA 2005; 294:3093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/75\">",
"      Halonen J, Loponen P, J&auml;rvinen O, et al. Metoprolol versus amiodarone in the prevention of atrial fibrillation after cardiac surgery: a randomized trial. Ann Intern Med 2010; 153:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/76\">",
"      Kerstein J, Soodan A, Qamar M, et al. Giving IV and oral amiodarone perioperatively for the prevention of postoperative atrial fibrillation in patients undergoing coronary artery bypass surgery: the GAP study. Chest 2004; 126:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/77\">",
"      Solomon AJ, Greenberg MD, Kilborn MJ, Katz NM. Amiodarone versus a beta-blocker to prevent atrial fibrillation after cardiovascular surgery. Am Heart J 2001; 142:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/78\">",
"      Blommaert D, Gonzalez M, Mucumbitsi J, et al. Effective prevention of atrial fibrillation by continuous atrial overdrive pacing after coronary artery bypass surgery. J Am Coll Cardiol 2000; 35:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/79\">",
"      Greenberg MD, Katz NM, Iuliano S, et al. Atrial pacing for the prevention of atrial fibrillation after cardiovascular surgery. J Am Coll Cardiol 2000; 35:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/80\">",
"      Fan K, Lee KL, Chiu CS, et al. Effects of biatrial pacing in prevention of postoperative atrial fibrillation after coronary artery bypass surgery. Circulation 2000; 102:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/81\">",
"      Daoud EG, Dabir R, Archambeau M, et al. Randomized, double-blind trial of simultaneous right and left atrial epicardial pacing for prevention of post-open heart surgery atrial fibrillation. Circulation 2000; 102:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/82\">",
"      Levy T, Fotopoulos G, Walker S, et al. Randomized controlled study investigating the effect of biatrial pacing in prevention of atrial fibrillation after coronary artery bypass grafting. Circulation 2000; 102:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/83\">",
"      Gerstenfeld EP, Hill MR, French SN, et al. Evaluation of right atrial and biatrial temporary pacing for the prevention of atrial fibrillation after coronary artery bypass surgery. J Am Coll Cardiol 1999; 33:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/84\">",
"      Chung MK, Augostini RS, Asher CR, et al. Ineffectiveness and potential proarrhythmia of atrial pacing for atrial fibrillation prevention after coronary artery bypass grafting. Ann Thorac Surg 2000; 69:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/85\">",
"      Weiner B, Rheinlander HF, Decker EL, Cleveland RJ. Digoxin prophylaxis following coronary artery bypass surgery. Clin Pharm 1986; 5:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/86\">",
"      Gold MR, O'Gara PT, Buckley MJ, DeSanctis RW. Efficacy and safety of procainamide in preventing arrhythmias after coronary artery bypass surgery. Am J Cardiol 1996; 78:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/87\">",
"      Laub GW, Janeira L, Muralidharan S, et al. Prophylactic procainamide for prevention of atrial fibrillation after coronary artery bypass grafting: a prospective, double-blind, randomized, placebo-controlled pilot study. Crit Care Med 1993; 21:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/88\">",
"      Davison R, Hartz R, Kaplan K, et al. Prophylaxis of supraventricular tachyarrhythmia after coronary bypass surgery with oral verapamil: a randomized, double-blind trial. Ann Thorac Surg 1985; 39:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/89\">",
"      Smith EE, Shore DF, Monro JL, Ross JK. Oral verapamil fails to prevent supraventricular tachycardia following coronary artery surgery. Int J Cardiol 1985; 9:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/90\">",
"      Malhotra R, Mishra M, Kler TS, et al. Cardioprotective effects of diltiazem infusion in the perioperative period. Eur J Cardiothorac Surg 1997; 12:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/91\">",
"      Seitelberger R, Hannes W, Gleichauf M, et al. Effects of diltiazem on perioperative ischemia, arrhythmias, and myocardial function in patients undergoing elective coronary bypass grafting. J Thorac Cardiovasc Surg 1994; 107:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/92\">",
"      Shiga T, Wajima Z, Inoue T, Ogawa R. Magnesium prophylaxis for arrhythmias after cardiac surgery: a meta-analysis of randomized controlled trials. Am J Med 2004; 117:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/93\">",
"      England MR, Gordon G, Salem M, Chernow B. Magnesium administration and dysrhythmias after cardiac surgery. A placebo-controlled, double-blind, randomized trial. JAMA 1992; 268:2395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/94\">",
"      Kaplan M, Kut MS, Icer UA, Demirtas MM. Intravenous magnesium sulfate prophylaxis for atrial fibrillation after coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 125:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/95\">",
"      Toraman F, Karabulut EH, Alhan HC, et al. Magnesium infusion dramatically decreases the incidence of atrial fibrillation after coronary artery bypass grafting. Ann Thorac Surg 2001; 72:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/96\">",
"      Hazelrigg SR, Boley TM, Cetindag IB, et al. The efficacy of supplemental magnesium in reducing atrial fibrillation after coronary artery bypass grafting. Ann Thorac Surg 2004; 77:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/97\">",
"      Cook RC, Humphries KH, Gin K, et al. Prophylactic intravenous magnesium sulphate in addition to oral {beta}-blockade does not prevent atrial arrhythmias after coronary artery or valvular heart surgery: a randomized, controlled trial. Circulation 2009; 120:S163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/98\">",
"      Pretorius M, Murray KT, Yu C, et al. Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery. Crit Care Med 2012; 40:2805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/99\">",
"      Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006; 114:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/100\">",
"      Liakopoulos OJ, Kuhn EW, Slottosch I, et al. Preoperative statin therapy for patients undergoing cardiac surgery. Cochrane Database Syst Rev 2012; 4:CD008493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/101\">",
"      Ozaydin M, Peker O, Erdogan D, et al. N-acetylcysteine for the prevention of postoperative atrial fibrillation: a prospective, randomized, placebo-controlled pilot study. Eur Heart J 2008; 29:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/102\">",
"      Ozaydin M, Icli A, Yucel H, et al. Metoprolol vs. carvedilol or carvedilol plus N-acetyl cysteine on post-operative atrial fibrillation: a randomized, double-blind, placebo-controlled study. Eur Heart J 2013; 34:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/103\">",
"      Imazio M, Brucato A, Ferrazzi P, et al. Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation 2011; 124:2290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/104\">",
"      Harling L, Rasoli S, Vecht JA, et al. Do antioxidant vitamins have an anti-arrhythmic effect following cardiac surgery? A meta-analysis of randomised controlled trials. Heart 2011; 97:1636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/105\">",
"      Horbach SJ, Lopes RD, da C Guaragna JC, et al. Naproxen as prophylaxis against atrial fibrillation after cardiac surgery: the NAFARM randomized trial. Am J Med 2011; 124:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/106\">",
"      Ho KM, Tan JA. Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose-response meta-analysis. Circulation 2009; 119:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/107\">",
"      Dieleman JM, van Paassen J, van Dijk D, et al. Prophylactic corticosteroids for cardiopulmonary bypass in adults. Cochrane Database Syst Rev 2011; :CD005566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/108\">",
"      Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006; 48:e149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/109\">",
"      Solomon AJ, Kouretas PC, Hopkins RA, et al. Early discharge of patients with new-onset atrial fibrillation after cardiovascular surgery. Am Heart J 1998; 135:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/110\">",
"      European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/111\">",
"      Geelen P, O'Hara GE, Roy N, et al. Comparison of propafenone versus procainamide for the acute treatment of atrial fibrillation after cardiac surgery. Am J Cardiol 1999; 84:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/112\">",
"      McAlister HF, Luke RA, Whitlock RM, Smith WM. Intravenous amiodarone bolus versus oral quinidine for atrial flutter and fibrillation after cardiac operations. J Thorac Cardiovasc Surg 1990; 99:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/113\">",
"      Gavaghan TP, Koegh AM, Kelly RP, et al. Flecainide compared with a combination of digoxin and disopyramide for acute atrial arrhythmias after cardiopulmonary bypass. Br Heart J 1988; 60:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/114\">",
"      Di Biasi P, Scrofani R, Paje A, et al. Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation. Eur J Cardiothorac Surg 1995; 9:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/115\">",
"      Campbell TJ, Gavaghan TP, Morgan JJ. Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomised trial. Br Heart J 1985; 54:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/116\">",
"      VanderLugt JT, Mattioni T, Denker S, et al. Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery. Circulation 1999; 100:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/117\">",
"      Yilmaz AT, Dem&iacute;rkili&ccedil; U, Arslan M, et al. Long-term prevention of atrial fibrillation after coronary artery bypass surgery: comparison of quinidine, verapamil, and amiodarone in maintaining sinus rhythm. J Card Surg 1996; 11:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/118\">",
"      Connolly SJ, Mulji AS, Hoffert DL, et al. Randomized placebo-controlled trial of propafenone for treatment of atrial tachyarrhythmias after cardiac surgery. J Am Coll Cardiol 1987; 10:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/119\">",
"      Hjelms E. Procainamide conversion of acute atrial fibrillation after open-heart surgery compared with digoxin treatment. Scand J Thorac Cardiovasc Surg 1992; 26:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/120\">",
"      Kollar A, Lick SD, Vasquez KN, Conti VR. Relationship of atrial fibrillation and stroke after coronary artery bypass graft surgery: when is anticoagulation indicated? Ann Thorac Surg 2006; 82:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/121\">",
"      Gohlke H, Gohlke-B&auml;rwolf C, St&uuml;rzenhofecker P, et al. Improved graft patency with anticoagulant therapy after aortocoronary bypass surgery: a prospective, randomized study. Circulation 1981; 64:II22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/122\">",
"      Weber MA, Hasford J, Taillens C, et al. Low-dose aspirin versus anticoagulants for prevention of coronary graft occlusion. Am J Cardiol 1990; 66:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/123\">",
"      Malouf JF, Alam S, Gharzeddine W, Stefadouros MA. The role of anticoagulation in the development of pericardial effusion and late tamponade after cardiac surgery. Eur Heart J 1993; 14:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/124\">",
"      Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011; 58:e123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/125\">",
"      Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33:2719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/59/28602/abstract/126\">",
"      Fuster V, Ryd&eacute;n LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1011 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-4563C940AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_59_28602=[""].join("\n");
var outline_f27_59_28602=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H194220665\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INCIDENCE AND TIME COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H266205047\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ADVERSE OUTCOMES FOLLOWING AF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PREVENTION OF AF AND COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H165339032\">",
"      Prevention of AF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Sotalol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Amiodarone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H165339288\">",
"      - Atrial pacing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H97330379\">",
"      - Ineffective or possibly effective therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H423952309\">",
"      Prevention of complications of AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H423952316\">",
"      Our approach to prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Rate control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Cardioversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H53913896\">",
"      - Patients on long-term anticoagulant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H53914044\">",
"      - Patients not taking anticoagulant prior to cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Our approach to postoperative anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97331689\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H194220665\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H346699792\">",
"      ACKOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1011\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1011|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/2/25645\" title=\"figure 1\">",
"      SAECG predicts atrial fibrillation post CABG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1011|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/58/9133\" title=\"table 1\">",
"      Post CABG AF risk index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/45/40668\" title=\"table 2\">",
"      CHADS2 score and thromboembolic risk with and without warfarin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20503?source=related_link\">",
"      ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=related_link\">",
"      Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23576?source=related_link\">",
"      Arrhythmias following cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=related_link\">",
"      Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=related_link\">",
"      Cardioversion for specific arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39368?source=related_link\">",
"      Early cardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37511?source=related_link\">",
"      Embolic risk and the role of anticoagulation in atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=related_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=related_link\">",
"      Fish oil and marine omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28249?source=related_link\">",
"      Glucocorticoid effects on the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=related_link\">",
"      Long-term outcome after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12266?source=related_link\">",
"      Mechanisms of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40360?source=related_link\">",
"      Medical therapy to prevent complications after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37031?source=related_link\">",
"      Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=related_link\">",
"      The electrocardiogram in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=related_link\">",
"      Therapeutic use and major side effects of sotalol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/44/713?source=related_link\">",
"      Treatment of acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/39/10872?source=related_link\">",
"      Use of the signal-averaged electrocardiogram in arrhythmia evaluation and management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_59_28603="Energy intake CKD children";
var content_f27_59_28603=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Equations to estimate energy requirements for children with chronic kidney disease at healthy weights",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Estimated energy requirement (EER) (kcal/day) = total energy expenditure + energy deposition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0 to 3 months",
"       </td>",
"       <td>",
"        EER = [89 x weight (kg) - 100] + 175",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 to 6 months",
"       </td>",
"       <td>",
"        EER = [89 x weight (kg) - 100] + 56",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7 to 12 months",
"       </td>",
"       <td>",
"        EER = [89 x weight (kg) - 100] + 22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13 to 35 months",
"       </td>",
"       <td>",
"        EER = [89 x weight (kg) - 100] + 20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        3 to 8 years",
"       </td>",
"       <td>",
"        Boys: EER = 88.5 - 61.9 x age (years) + PA x [26.7 x weight (kg) + 903 x height (m)] + 20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Girls: EER = 135.3 - 30.8 x age (years) + PA x [10 x weight (kg) + 934 x height (m)] + 20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        9 to 18 years",
"       </td>",
"       <td>",
"        Boys: EER = 88.5 - 61.9 x age (years) + PA x [26.7 x weight (kg) + 903 x height (m)] + 25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Girls: EER = 135.3 - 30.8 x age (years) + PA x [10 x weight (kg) + 934 x height (m)] + 25",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: National Kidney Foundation. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary. Am J Kidney Dis 2009; 53:S11. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_59_28603=[""].join("\n");
var outline_f27_59_28603=null;
var title_f27_59_28604="Chemicals associated with ocular burns";
var content_f27_59_28604=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chemicals commonly associated with ocular burns",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Chemical substance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Typical use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Alkali",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ammonia hydroxide (anhydrous ammonia)",
"       </td>",
"       <td>",
"        <p>",
"         Cleansers",
"        </p>",
"        <p>",
"         Fertilizer",
"        </p>",
"        <p>",
"         Hair dyes and tints",
"        </p>",
"        <p>",
"         Floor strippers",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Calcium carbonate or magnesium carbonate",
"       </td>",
"       <td>",
"        Lime soil treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Calcium hydroxide",
"       </td>",
"       <td>",
"        Cement, plaster, or mortar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Sodium hydroxide",
"        </p>",
"        <p>",
"         Potassium hydroxide",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Lye cleansers",
"        </p>",
"        <p>",
"         Oven or drain cleaners",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Sodium hypochlorite (70 percent)",
"        </p>",
"        <p>",
"         Calcium hypochlorite (70 percent)",
"        </p>",
"       </td>",
"       <td>",
"        Swimming pool cleaner",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sodium hypochlorite (3 to 15 percent)*",
"       </td>",
"       <td>",
"        Bleach",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sodium tripolyphosphate",
"       </td>",
"       <td>",
"        Automatic dishwasher detergent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Acids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acetic acid",
"       </td>",
"       <td>",
"        Permanent hair wave neutralizers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hydrochloric acid (muriatic acid)",
"       </td>",
"       <td>",
"        <p>",
"         Toilet bowl cleaner",
"        </p>",
"        <p>",
"         Grout cleaner",
"        </p>",
"        <p>",
"         Rust stain remover",
"        </p>",
"        <p>",
"         Swimming pool cleaner",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hydrofluoric acid",
"       </td>",
"       <td>",
"        <p>",
"         Glass etching",
"        </p>",
"        <p>",
"         Rust remover",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phosphoric acid",
"       </td>",
"       <td>",
"        <p>",
"         Rust remover",
"        </p>",
"        <p>",
"         Toilet bowel cleaner",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sulfuric acid (30 to 70 percent)",
"       </td>",
"       <td>",
"        <p>",
"         Toilet bowl cleaner",
"        </p>",
"        <p>",
"         Car battery fluid",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Industrial strength bleach is up to 15 percent concentration.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Farjo, AA, Soong, HK. Corneal epithelium. In: Ophthalmology, 2nd ed, Yanoff, M, Duker, JS (Eds), Mosby, St. Louis, MO 2004. p. 413.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_59_28604=[""].join("\n");
var outline_f27_59_28604=null;
var title_f27_59_28605="TMLR freedom rehospitalization";
var content_f27_59_28605=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transmyocardial laser revascularization reduces cardiac-related rehospitalizations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 266px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of 275 patients with refractory angina, Kaplan-Meier estimates show that freedom from cardiac-related rehospitalization at one year was higher with transmyocardial laser revascularization (TMLR) compared to medical therapy (61 versus 33 percent, p &lt;0.001).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Allen KB, Dowling RD, Fudge TL, et al. N Engl J Med 1999; 341:1029.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_59_28605=[""].join("\n");
var outline_f27_59_28605=null;
var title_f27_59_28606="Drug and toxin related movement disorders";
var content_f27_59_28606=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug- and toxin-induced movement disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Seizures",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Beta-blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Insecticides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lidocaine and other local anesthetics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Sympathomimetics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cocaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Amphetamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Theophylline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Caffeine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Nicotine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Drug withdrawal states",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Antidepressants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            TCAs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Bupropion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Citalopram",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Escitalopram",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Fluvoxamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Venlafaxine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Amoxapine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Maprotiline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Antipsychotics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Phenothiazines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Clozapine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Local anesthetics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Salicylates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Camphor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Isoniazid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lithium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypoglycemic agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cyanide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carbon monoxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Meperidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Propoxyphene",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Orphenadrine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antihistamines (rare)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lindane",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gyromitra-containing mushrooms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Heavy metals",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Antimicrobials",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Imipenem",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Penicillins",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Tremors/myoclonus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lithium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antipsychotics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Sympathomimetics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cocaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Theophylline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Amphetamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Caffeine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Albuterol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Methylphenidate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cathinones",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Anticholinergics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Antihistamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            TCAs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Drug Withdrawal states",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Heavy metals",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Rigidity/parkinsonism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antipsychotics (neuroleptics)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Metoclopramide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amoxapine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carbon monoxide (delayed)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methanol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ethylene glycol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phencyclidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            MAOIs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Serotonin syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Black widow spider bite",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lithium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methaqualone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            MPTP (designer meperidine)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Manganese",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Strychnine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carbon disulfide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cyanide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Malignant hyperthermia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neuroleptic malignant syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Postanoxic injury from any agent",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Choreoathetosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Anticholinergics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            TCAs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Antihistamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Antiepileptics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Phenytoin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Carbamazepine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Weakness/paralysis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Barium (hypokalemia)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Magnesium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Solvent abuse",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Toluene",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Gasoline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Heavy metals",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Mercury",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Thallium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Insecticides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Organophosphates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Carbamates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nicotine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Botulism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neurotoxic snake envenomation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tick paralysis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Seafood poisoning",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Paralytic shellfish",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Pufferfish (fugu)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_59_28606=[""].join("\n");
var outline_f27_59_28606=null;
var title_f27_59_28607="Apical 4 chamber echo right atrial thrombus";
var content_f27_59_28607=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Apical 4 chamber echocardiogram showing right atrial thrombus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 327px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The apical four chamber view show a thrombus that was in transit from the lower extremities and temporarily became lodged in the right atrium (RA). Additionally, the right ventricle (RA) is enlarged, implying that other emboli have reached the pulmonary circulation, resulting in raised pulmonary vascular resistance.",
"    <div class=\"footnotes\">",
"     LV: left ventricle; LA: left atrium.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_59_28607=[""].join("\n");
var outline_f27_59_28607=null;
